id,type,description,contributions,reportedIn,direction,indication.id,indication.indication,indication.initial_approval_date,indication.initial_approval_url,indication.description,indication.raw_biomarkers,indication.raw_cancer_type,indication.raw_therapeutics,indication.icd10,indication.regimen_code,indication.reimbursement_category,indication.reimbursement_date,indication.reimbursement_details,indication.date_regular_approval,indication.date_accelerated_approval,indication.document.id,indication.document.type,indication.document.subtype,indication.document.name,indication.document.citation,indication.document.company,indication.document.drug_name_brand,indication.document.drug_name_generic,indication.document.first_published,indication.document.access_date,indication.document.publication_date,indication.document.url,indication.document.url_drug,indication.document.application_number,indication.document.organization.id,indication.document.organization.name,indication.document.organization.description,indication.document.organization.url,indication.document.organization.last_updated,proposition.id,proposition.type,proposition.predicate,proposition.biomarkers,proposition.conditionQualifier.id,proposition.conditionQualifier.conceptType,proposition.conditionQualifier.name,proposition.conditionQualifier.primaryCoding.id,proposition.conditionQualifier.primaryCoding.code,proposition.conditionQualifier.primaryCoding.name,proposition.conditionQualifier.primaryCoding.system,proposition.conditionQualifier.primaryCoding.systemVersion,proposition.conditionQualifier.primaryCoding.iris,proposition.conditionQualifier.mappings,proposition.objectTherapeutic.id,proposition.objectTherapeutic.membership_operator,proposition.objectTherapeutic.therapies,proposition.objectTherapeutic.conceptType,proposition.objectTherapeutic.name,proposition.objectTherapeutic.primaryCoding.id,proposition.objectTherapeutic.primaryCoding.code,proposition.objectTherapeutic.primaryCoding.name,proposition.objectTherapeutic.primaryCoding.system,proposition.objectTherapeutic.primaryCoding.systemVersion,proposition.objectTherapeutic.primaryCoding.iris,proposition.objectTherapeutic.mappings,proposition.objectTherapeutic.extensions,agency
2000,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.adcetris:0,"ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",,,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.",CD30-expressing,"systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)","Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)",,,,,,,,doc:hc.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [product monograph]. HC.,Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.,Seagen Inc.,Adcetris,brentuximab vedotin,,2025-06-11,2025-04-08,https://pdf.hres.ca/dpd_pm/00080158.PDF,https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,48,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",3,Disease,Anaplastic Large Cell Lymphoma,oncotree:ALCL,ALCL,Anaplastic Large Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALCL'],[],11,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primaryCoding': {'id': 'ncit:C66944', 'code': 'C66944', 'name': 'Brentuximab Vedotin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2001,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.adcetris:0,"ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",,,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.",CD30-expressing,"systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)","Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)",,,,,,,,doc:hc.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [product monograph]. HC.,Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.,Seagen Inc.,Adcetris,brentuximab vedotin,,2025-06-11,2025-04-08,https://pdf.hres.ca/dpd_pm/00080158.PDF,https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,847,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",92,Disease,Angioimmunoblastic T-Cell Lymphoma,oncotree:AITL,AITL,Angioimmunoblastic T-Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2025_04_08,['https://oncotree.mskcc.org/?version=oncotree_2025_04_08&field=NAME&search=Angioimmunoblastic+T-Cell+Lymphoma+%28AITL%29'],[],11,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primaryCoding': {'id': 'ncit:C66944', 'code': 'C66944', 'name': 'Brentuximab Vedotin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2002,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.adcetris:0,"ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",,,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.",CD30-expressing,"systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)","Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)",,,,,,,,doc:hc.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [product monograph]. HC.,Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.,Seagen Inc.,Adcetris,brentuximab vedotin,,2025-06-11,2025-04-08,https://pdf.hres.ca/dpd_pm/00080158.PDF,https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,848,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",93,Disease,"Peripheral T-Cell lymphoma, NOS",oncotree:PTCL,PTCL,"Peripheral T-Cell lymphoma, NOS",https://oncotree.mskcc.org,oncotree_2025_04_08,['https://oncotree.mskcc.org/?version=oncotree_2025_04_08&field=NAME&search=Peripheral+T-Cell+lymphoma%2C+NOS+%28PTCL%29'],[],11,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primaryCoding': {'id': 'ncit:C66944', 'code': 'C66944', 'name': 'Brentuximab Vedotin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2003,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.adcetris:1,ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy,,,Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.,CD30-expressing,CD30-Expressing Mycosis Fungoides (MF),Adcetris (brentuximab vedotin),,,,,,,,doc:hc.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [product monograph]. HC.,Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.,Seagen Inc.,Adcetris,brentuximab vedotin,,2025-06-11,2025-04-08,https://pdf.hres.ca/dpd_pm/00080158.PDF,https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,841,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",91,Disease,Mycosis Fungoides,oncotree:MYCF,MYCF,Mycosis Fungoides,https://oncotree.mskcc.org,oncotree_2025_04_08,['https://oncotree.mskcc.org/?version=oncotree_2025_04_08&field=NAME&search=Mycosis+Fungoides+%28MYCF%29'],[],11,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primaryCoding': {'id': 'ncit:C66944', 'code': 'C66944', 'name': 'Brentuximab Vedotin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2004,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.afinitor:0,"AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",,,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","HR+, HER2-negative",advanced breast cancer,Afinitor (everolimus) in combination with exemestane,,,,,,,,doc:hc.afinitor,Document,Regulatory approval,Afinitor (everolimus) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Afinitor,everolimus,2009-12-11,2025-06-11,2021-11-30,https://pdf.hres.ca/dpd_pm/00063824.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,131,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2005,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.afinitor:0,"AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",,,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","HR+, HER2-negative",advanced breast cancer,Afinitor (everolimus) in combination with exemestane,,,,,,,,doc:hc.afinitor,Document,Regulatory approval,Afinitor (everolimus) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Afinitor,everolimus,2009-12-11,2025-06-11,2021-11-30,https://pdf.hres.ca/dpd_pm/00063824.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,132,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2006,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.afinitor:0,"AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",,,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","HR+, HER2-negative",advanced breast cancer,Afinitor (everolimus) in combination with exemestane,,,,,,,,doc:hc.afinitor,Document,Regulatory approval,Afinitor (everolimus) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Afinitor,everolimus,2009-12-11,2025-06-11,2021-11-30,https://pdf.hres.ca/dpd_pm/00063824.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,133,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2007,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.alecensaro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensaro (alectinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Alecensaro', 'drug_name_generic': 'alectinib', 'first_published': '2016-09-29', 'access_date': '2025-06-13', 'publication_date': '2025-03-11', 'url': 'https://pdf.hres.ca/dpd_pm/00078825.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.alecensaro:0,"ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",,,"Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.",ALK-positive,metastatic non-small cell lung cancer,Alecensaro (alectinib),,,,,,,,doc:hc.alecensaro,Document,Regulatory approval,Alecensaro (alectinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Alecensaro,alectinib,2016-09-29,2025-06-13,2025-03-11,https://pdf.hres.ca/dpd_pm/00078825.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,22,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],9,,,Drug,Alectinib,ncit:C101790,C101790,Alectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2008,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.alunbrig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alunbrig (brigatinib) [product monograph]. HC.', 'citation': 'Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.', 'company': 'Takeda Canada Inc.', 'drug_name_brand': 'Alunbrig', 'drug_name_generic': 'brigatinib', 'first_published': '2018-07-25', 'access_date': '2025-06-13', 'publication_date': '2022-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00066731.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.alunbrig:0,ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,,,"Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.",ALK-positive,metastatic non-small cell lung cancer,Alunbrig (brigatinib),,,,,,,,doc:hc.alunbrig,Document,Regulatory approval,Alunbrig (brigatinib) [product monograph]. HC.,Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.,Takeda Canada Inc.,Alunbrig,brigatinib,2018-07-25,2025-06-13,2022-07-19,https://pdf.hres.ca/dpd_pm/00066731.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,50,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],10,,,Drug,Brigatinib,ncit:C98831,C98831,Brigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98831'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2009,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Augtyro (repotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080483.PDF. Published May 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': '2025-05-07', 'access_date': '2025-06-23', 'publication_date': '2025-05-07', 'url': 'https://pdf.hres.ca/dpd_pm/00080483.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106076', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.augtyro:0,AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,,,Health Canada approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,ROS1-positive,locally advanced or metastatic non-small cell lung cancer,Augtyro (repotrectinib),,,,,,,,doc:hc.augtyro,Document,Regulatory approval,Augtyro (repotrectinib) [product monograph]. HC.,Bristol-Myers Squibb Canada. Augtyro (repotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080483.PDF. Published May 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Augtyro,repotrectinib,2025-05-07,2025-06-23,2025-05-07,https://pdf.hres.ca/dpd_pm/00080483.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106076,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,368,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],134,,,Drug,Repotrectinib,ncit:C133821,C133821,Repotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C133821'],[],"[{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2010,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.balversa:0,"BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",,,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",susceptible FGFR3 genetic alterations,locally advanced unresectable or metastatic urothelial carcinoman (UC),Balversa (erdafitinib),,,,,,,,doc:hc.balversa,Document,Regulatory approval,Balversa (erdafitinib) [product monograph]. HC.,Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.,Janssen Inc.,Balversa,erdafitinib,2019-10-25,2025-06-12,2024-11-20,https://pdf.hres.ca/dpd_pm/00077812.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,124,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 99, 'name': 'FGFR3 p.R248C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803564}, {'name': 'end_position', 'value': 1803564}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.742C>T'}, {'name': 'protein_change', 'value': 'p.R248C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '6'}, {'name': 'rsid', 'value': 'rs121913482'}, {'name': 'hgvsg', 'value': '4:g.1803564C>T'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2011,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.balversa:0,"BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",,,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",susceptible FGFR3 genetic alterations,locally advanced unresectable or metastatic urothelial carcinoman (UC),Balversa (erdafitinib),,,,,,,,doc:hc.balversa,Document,Regulatory approval,Balversa (erdafitinib) [product monograph]. HC.,Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.,Janssen Inc.,Balversa,erdafitinib,2019-10-25,2025-06-12,2024-11-20,https://pdf.hres.ca/dpd_pm/00077812.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,125,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 100, 'name': 'FGFR3 p.S249C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803568}, {'name': 'end_position', 'value': 1803568}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.746C>G'}, {'name': 'protein_change', 'value': 'p.S249C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '6'}, {'name': 'rsid', 'value': 'rs121913483'}, {'name': 'hgvsg', 'value': '4:g.1803568C>G'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2012,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.balversa:0,"BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",,,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",susceptible FGFR3 genetic alterations,locally advanced unresectable or metastatic urothelial carcinoman (UC),Balversa (erdafitinib),,,,,,,,doc:hc.balversa,Document,Regulatory approval,Balversa (erdafitinib) [product monograph]. HC.,Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.,Janssen Inc.,Balversa,erdafitinib,2019-10-25,2025-06-12,2024-11-20,https://pdf.hres.ca/dpd_pm/00077812.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,126,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 101, 'name': 'FGFR3 p.G370C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806089}, {'name': 'end_position', 'value': 1806089}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1108G>T'}, {'name': 'protein_change', 'value': 'p.G370C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '8'}, {'name': 'rsid', 'value': 'rs121913479'}, {'name': 'hgvsg', 'value': '4:g.1806089G>T'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2013,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.balversa:0,"BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",,,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",susceptible FGFR3 genetic alterations,locally advanced unresectable or metastatic urothelial carcinoman (UC),Balversa (erdafitinib),,,,,,,,doc:hc.balversa,Document,Regulatory approval,Balversa (erdafitinib) [product monograph]. HC.,Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.,Janssen Inc.,Balversa,erdafitinib,2019-10-25,2025-06-12,2024-11-20,https://pdf.hres.ca/dpd_pm/00077812.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,127,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 102, 'name': 'FGFR3 p.Y373C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806099}, {'name': 'end_position', 'value': 1806099}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.1118A>G'}, {'name': 'protein_change', 'value': 'p.Y373C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '8'}, {'name': 'rsid', 'value': 'rs121913485'}, {'name': 'hgvsg', 'value': '4:g.1806099A>G'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2014,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.balversa:0,"BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",,,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",susceptible FGFR3 genetic alterations,locally advanced unresectable or metastatic urothelial carcinoman (UC),Balversa (erdafitinib),,,,,,,,doc:hc.balversa,Document,Regulatory approval,Balversa (erdafitinib) [product monograph]. HC.,Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.,Janssen Inc.,Balversa,erdafitinib,2019-10-25,2025-06-12,2024-11-20,https://pdf.hres.ca/dpd_pm/00077812.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,128,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 97, 'name': 'FGFR3::TACC3', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}, {'id': 51, 'name': 'TACC3', 'primaryCoding': {'id': 'hgnc:11524', 'code': 'HGNC:11524', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11524']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006342.3', 'code': 'NM_006342.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006342.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000013810', 'code': 'ENSG00000013810', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000013810']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:10460', 'code': '10460', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/10460']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2015,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.besponsa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Besponsa (inotuzumab ozogamicin) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Besponsa', 'drug_name_generic': 'inotuzumab ozogamicin', 'first_published': '2018-03-15', 'access_date': '2025-06-12', 'publication_date': '2024-11-08', 'url': 'https://pdf.hres.ca/dpd_pm/00077730.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.besponsa:0,BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,,,Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,CD22-positive,B-cell precursor acute lymphoblastic leukemia,Besponsa (inotuzumab ozogamicin),,,,,,,,doc:hc.besponsa,Document,Regulatory approval,Besponsa (inotuzumab ozogamicin) [product monograph]. HC.,Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.,Pfizer Canada ULC,Besponsa,inotuzumab ozogamicin,2018-03-15,2025-06-12,2024-11-08,https://pdf.hres.ca/dpd_pm/00077730.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,168,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 13, 'name': 'CD22 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD22'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],14,,,Drug,Inotuzumab ozogamicin,ncit:C71542,C71542,Inotuzumab Ozogamicin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71542'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2016,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [product monograph]. HC.', 'citation': 'Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2015-12-22', 'access_date': '2025-06-12', 'publication_date': '2024-12-27', 'url': 'https://pdf.hres.ca/dpd_pm/00078156.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.blincyto:2,BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.,,,Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,CD19-positive,B-cell precursor acute lymphoblastic leukemia (ALL),Blincyto (blinatumomab),,,,,,,,doc:hc.blincyto,Document,Regulatory approval,Blincyto (blinatumomab) [product monograph]. HC.,Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.,Amgen Canada Inc.,Blincyto,blinatumomab,2015-12-22,2025-06-12,2024-12-27,https://pdf.hres.ca/dpd_pm/00078156.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,45,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 14, 'name': 'CD19 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD19'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],15,,,Drug,Blinatumomab,ncit:C62528,C62528,Blinatumomab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528'],[],"[{'name': 'therapy_strategy', 'value': ['CD19 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2017,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.bosulif:0,BOSULIF (bosutinib) is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).,,,Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).,philadelphia chromosome-positive (Ph+),chronic myelogenous leukemia,Bosulif (bosutinib),,,,,,,,doc:hc.bosulif,Document,Regulatory approval,Bosulif (bosutinib) [product monograph]. HC.,Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.,Pfizer Canada ULC,Bosulif,bosutinib,2014-03-07,2025-06-12,2024-07-12,https://pdf.hres.ca/dpd_pm/00076285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,47,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],16,,,Drug,Bosutinib,ncit:C60809,C60809,Bosutinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2018,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.bosulif:1,"BOSULIF (bosutinib) is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.",,,"Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.",philadelphia chromosone-positive (Ph+),chronic myelogenous leukemia,Bosulif (bosutinib),,,,,,,,doc:hc.bosulif,Document,Regulatory approval,Bosulif (bosutinib) [product monograph]. HC.,Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.,Pfizer Canada ULC,Bosulif,bosutinib,2014-03-07,2025-06-12,2024-07-12,https://pdf.hres.ca/dpd_pm/00076285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,47,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],16,,,Drug,Bosutinib,ncit:C60809,C60809,Bosutinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2019,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.braftovi:0,"BRAFTOVI (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",,,"Health Canada approved encorafenib in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",BRAF V600E or BRAF V600K,unresectable or metastatic melanoma,Braftovi (encorafenib) in combination with binimetinib,,,,,,,,doc:hc.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [product monograph]. HC.,Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.,Pfizer Canada ULC,Braftovi,encorafenib,2021-03-02,2025-06-12,2024-02-23,https://pdf.hres.ca/dpd_pm/00074711.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,41,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2020,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.braftovi:1,"BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.",,,"Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.",BRAF V600E,metastatic colorectal cancer (mCRC),Braftovi (encorafenib) in combination with cetuximab,,,,,,,,doc:hc.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [product monograph]. HC.,Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.,Pfizer Canada ULC,Braftovi,encorafenib,2021-03-02,2025-06-12,2024-02-23,https://pdf.hres.ca/dpd_pm/00074711.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,81,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],16,AND,"[{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2021,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.cotellic:0,COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,,,Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,BRAF V600 mutation,unresectable or metastatic melanoma,Cotellic in combination with vemurafenib,,,,,,,,doc:hc.cotellic,Document,Regulatory approval,Cotellic (cobimetinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Cotellic,cobimetinib,2016-02-22,2025-06-12,2023-03-24,https://pdf.hres.ca/dpd_pm/00070061.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,82,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],17,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2022,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.cotellic:0,COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,,,Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,BRAF V600 mutation,unresectable or metastatic melanoma,Cotellic in combination with vemurafenib,,,,,,,,doc:hc.cotellic,Document,Regulatory approval,Cotellic (cobimetinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Cotellic,cobimetinib,2016-02-22,2025-06-12,2023-03-24,https://pdf.hres.ca/dpd_pm/00070061.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,83,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],17,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2023,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.enhertu:0,"ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",,,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",HER2-positive,unresectable or metastatic breast cancer,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:hc.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [product monograph]. HC.,AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Enhertu,trastuzumab deruxtecan,2021-04-15,2025-06-12,2025-01-17,https://pdf.hres.ca/dpd_pm/00078361.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,420,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2024,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.enhertu:1,ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).,,,Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).,HER2-positive,unresectable or metastatic breast cancer,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:hc.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [product monograph]. HC.,AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Enhertu,trastuzumab deruxtecan,2021-04-15,2025-06-12,2025-01-17,https://pdf.hres.ca/dpd_pm/00078361.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,420,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2025,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.enhertu:0,"ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",,,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",HER2-positive,unresectable or metastatic breast cancer,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:hc.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [product monograph]. HC.,AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Enhertu,trastuzumab deruxtecan,2021-04-15,2025-06-12,2025-01-17,https://pdf.hres.ca/dpd_pm/00078361.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,421,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 22, 'name': 'HER2-low', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Low'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2026,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.enhertu:3,"ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",,,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable,locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",HER2-positive,unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:hc.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [product monograph]. HC.,AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Enhertu,trastuzumab deruxtecan,2021-04-15,2025-06-12,2025-01-17,https://pdf.hres.ca/dpd_pm/00078361.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,423,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2027,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.erbitux:0,"ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.",,,"Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.","EGFR-expressing, K-Ras wild type",metastatic colorectal carcinoma (mCRC),"Erbitux (cetuximab) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)",,,,,,,,doc:hc.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [product monograph]. HC.,ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.,ImClone LLC,Erbitux,cetuximab,2018-01-10,2025-06-12,2018-01-10,https://pdf.hres.ca/dpd_pm/00043071.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,78,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],14,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primaryCoding': {'id': 'ncit:C62040', 'code': 'C62040', 'name': 'Irinotecan', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2028,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.erbitux:1,ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.,,,Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.,"EGFR-expressing, K-Ras wild type",metastatic colorectal carcinoma (mCRC),Erbitux (cetuximab) in combination with irinotecan,,,,,,,,doc:hc.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [product monograph]. HC.,ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.,ImClone LLC,Erbitux,cetuximab,2018-01-10,2025-06-12,2018-01-10,https://pdf.hres.ca/dpd_pm/00043071.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,79,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],15,AND,"[{'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primaryCoding': {'id': 'ncit:C62040', 'code': 'C62040', 'name': 'Irinotecan', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2029,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.erbitux:2,ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).,,,Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who are intolerant to irinotecan-based chemotherapy.,"EGFR-expressing, K-Ras wild type",metastatic colorectal carcinoma (mCRC),Erbitux (cetuximab) as a single agent,,,,,,,,doc:hc.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [product monograph]. HC.,ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.,ImClone LLC,Erbitux,cetuximab,2018-01-10,2025-06-12,2018-01-10,https://pdf.hres.ca/dpd_pm/00043071.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,80,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],19,,,Drug,Cetuximab,ncit:C1723,C1723,Cetuximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2030,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.erbitux:3,ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.,,,Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.,"EGFR-expressing, K-Ras wild type",metastatic colorectal carcinoma (mCRC),Erbitux (cetuximab) as a single agent,,,,,,,,doc:hc.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [product monograph]. HC.,ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.,ImClone LLC,Erbitux,cetuximab,2018-01-10,2025-06-12,2018-01-10,https://pdf.hres.ca/dpd_pm/00043071.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,80,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],19,,,Drug,Cetuximab,ncit:C1723,C1723,Cetuximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2031,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2025-06-12', 'publication_date': '2019-11-15', 'url': 'https://pdf.hres.ca/dpd_pm/00053975.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.faslodex:0,"FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.",,,"Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.","estrogen receptor-positive (ER+), HER2-negative",locally advanced or metastatic breast cancer,Faslodex (fulvestrant),,,,,,,,doc:hc.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [product monograph]. HC.,AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.,AstraZeneca Canada Inc.,Faslodex,fulvestrant,,2025-06-12,2019-11-15,https://pdf.hres.ca/dpd_pm/00053975.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,134,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2032,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.giotrif:0,GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,,,Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,"EGFR Del 19, EGFR exon 21 L858R",metastatic adenocarcinoma of the lung,Giotrif (afatinib),,,,,,,,doc:hc.giotrif,Document,Regulatory approval,Giotrif (afatinib) [product monograph]. HC.,Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.,Boehringer Ingelheim (Canada) Ltd,Giotrif,afatinib,,2025-06-12,2019-06-06,https://pdf.hres.ca/dpd_pm/00051644.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,21,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 72, 'name': 'EGFR somatic variants', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],34,,,Drug,Afatinib,ncit:C66940,C66940,Afatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66940'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2033,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.giotrif:0,GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,,,Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,"EGFR Del 19, EGFR exon 21 L858R",metastatic adenocarcinoma of the lung,Giotrif (afatinib),,,,,,,,doc:hc.giotrif,Document,Regulatory approval,Giotrif (afatinib) [product monograph]. HC.,Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.,Boehringer Ingelheim (Canada) Ltd,Giotrif,afatinib,,2025-06-12,2019-06-06,https://pdf.hres.ca/dpd_pm/00051644.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,560,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 19, 'name': 'EGFR oncogenic variants', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],34,,,Drug,Afatinib,ncit:C66940,C66940,Afatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66940'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2034,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:0,"GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.",,,"Health Canada approved imatinib mesylate for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.",philadelphia chromosome-positive,chronic myeloid leukemia,Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,158,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2035,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:1,"GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.",,,"Health Canada approved imatinib mesylate for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.",Philadelphia chromosome-positive,chronic myeloid leukemia (CML),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,158,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2036,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:2,GLEEVEC (imatinib mesylate) is indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).,,,Health Canada approved imatinib mesylate ,Philadelphia chromosome-positive,acute lymphoblastic leukemia,Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,160,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2037,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:3,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.,Philadelphia chromosome-positive,acute lymphoblastic leukemia (Ph+ALL),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,160,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2038,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:4,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,DGFR gene re-arrangements,myelodysplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,161,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 28, 'name': 'PDGFRA rearrangements', 'genes': [{'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2039,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:4,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,DGFR gene re-arrangements,myelodysplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,162,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 29, 'name': 'PDGFRB rearrangements', 'genes': [{'id': 40, 'name': 'PDGFRB', 'primaryCoding': {'id': 'hgnc:8804', 'code': 'HGNC:8804', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8804']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000113721', 'code': 'ENSG00000113721', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000113721']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5159', 'code': '5159', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5159']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002609.4', 'code': 'NM_002609.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002609.4']}}], 'extensions': [{'name': 'location', 'value': '5q32'}, {'name': 'location_sortable', 'value': '05q32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2040,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:4,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,DGFR gene re-arrangements,myelodysplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,580,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 28, 'name': 'PDGFRA rearrangements', 'genes': [{'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",45,Disease,Myeloproliferative Neoplasm,oncotree:MPN,MPN,Myeloproliferative Neoplasm,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MPN'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2041,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:4,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,DGFR gene re-arrangements,myelodysplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,581,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 29, 'name': 'PDGFRB rearrangements', 'genes': [{'id': 40, 'name': 'PDGFRB', 'primaryCoding': {'id': 'hgnc:8804', 'code': 'HGNC:8804', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8804']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000113721', 'code': 'ENSG00000113721', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000113721']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5159', 'code': '5159', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5159']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002609.4', 'code': 'NM_002609.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002609.4']}}], 'extensions': [{'name': 'location', 'value': '5q32'}, {'name': 'location_sortable', 'value': '05q32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",45,Disease,Myeloproliferative Neoplasm,oncotree:MPN,MPN,Myeloproliferative Neoplasm,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MPN'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2042,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:5,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.,without D816V c-Kit mutation or with the c-Kit mutational status unknown,systemic mastocytosis (ASM and SMAHNMD),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,163,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 122, 'name': 'KIT p.D816V', 'genes': [{'id': 30, 'name': 'KIT', 'primaryCoding': {'id': 'hgnc:6342', 'code': 'HGNC:6342', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6342']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157404', 'code': 'ENSG00000157404', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157404']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3815', 'code': '3815', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3815']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000222.3', 'code': 'NM_000222.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000222.3']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 55599321}, {'name': 'end_position', 'value': 55599321}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2447A>T'}, {'name': 'protein_change', 'value': 'p.D816V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '17'}, {'name': 'rsid', 'value': 'rs121913507'}, {'name': 'hgvsg', 'value': '4:g.55599321A>T'}]}]",42,Disease,Aggressive Systemic Mastocytosis,oncotree:ASM,ASM,Aggressive Systemic Mastocytosis,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASM'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2043,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:6,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.,,,Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.,FIP1L1::PDGFRA rearrangement,advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,164,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 30, 'name': 'FIP1L1::PDGFRA', 'genes': [{'id': 25, 'name': 'FIP1L1', 'primaryCoding': {'id': 'hgnc:19124', 'code': 'HGNC:19124', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19124']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_030917.4', 'code': 'NM_030917.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_030917.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000145216', 'code': 'ENSG00000145216', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000145216']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:81608', 'code': '81608', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/81608']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}, {'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",12,Disease,"Chronic Eosinophilic Leukemia, NOS",oncotree:CELNOS,CELNOS,"Chronic Eosinophilic Leukemia, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CELNOS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2044,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:7,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,,,Health Canada approved imatinib mesylate for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,Kit (CD117) positive,unresectable and/or metastatic malignant gastrointestinal stromal tumors,Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,165,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 31, 'name': 'CD117 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD117'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2045,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.gleevec:8,GLEEVEC (imatinib mesylate) is indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.,,,Health Canada approved imatinib mesylate for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.,Kit (CD117) positive,gastrointestinal stromal tumors (GIST),Gleevec (imatinib mesylate),,,,,,,,doc:hc.gleevec,Document,Regulatory approval,Gleevec (imatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Gleevec,imatinib,2001-09-19,2025-06-12,2021-08-31,https://pdf.hres.ca/dpd_pm/00067276.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,165,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 31, 'name': 'CD117 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD117'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2046,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.herceptin:0,"HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.",,,"Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.",HER2-overexpressing,early stage breast cancer,Herceptin (trastuzumab),,,,,,,,doc:hc.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Herceptin,trastuzumab,1999-08-13,2025-06-12,2025-05-02,https://pdf.hres.ca/dpd_pm/00080472.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,418,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],25,,,Drug,Trastuzumab,ncit:C1647,C1647,Trastuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2047,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.herceptin:1,"HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",,,"Health Canada approved trastuzumab in combination with paclitaxel or docetaxel for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide.",HER2 overexpression,early stage breast cancer,"Herceptin (trastuzumab), paclitaxel, docetaxel",,,,,,,,doc:hc.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Herceptin,trastuzumab,1999-08-13,2025-06-12,2025-05-02,https://pdf.hres.ca/dpd_pm/00080472.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,842,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],183,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2048,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.herceptin:2,"HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.",,,"Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.",HER2 overexpression,early stage breast cancer,"Herceptin (trastuzumab), docetaxel, carboplatin",,,,,,,,doc:hc.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Herceptin,trastuzumab,1999-08-13,2025-06-12,2025-05-02,https://pdf.hres.ca/dpd_pm/00080472.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,563,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],112,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2049,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.herceptin:3,HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.,,,Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.,HER2-overexpressing,metastatic breast cancer,Herceptin (trastuzumab),,,,,,,,doc:hc.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Herceptin,trastuzumab,1999-08-13,2025-06-12,2025-05-02,https://pdf.hres.ca/dpd_pm/00080472.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,418,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],25,,,Drug,Trastuzumab,ncit:C1647,C1647,Trastuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2050,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.herceptin:4,HERCEPTIN (trastuzumab for injection) can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,,,Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,HER2-positive,metastatic breast cancer,"Herceptin (trastuzumab), pertuzumab, docetaxel",,,,,,,,doc:hc.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Herceptin,trastuzumab,1999-08-13,2025-06-12,2025-05-02,https://pdf.hres.ca/dpd_pm/00080472.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2051,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:0,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",,,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), aromatase inhibitor",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,311,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2052,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:0,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",,,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), aromatase inhibitor",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,312,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2053,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:0,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",,,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), aromatase inhibitor",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,313,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2054,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:1,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",,,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), fulvestrant",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,143,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2055,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:1,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",,,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), fulvestrant",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,144,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2056,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.ibrance:1,"IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",,,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Ibrance (palbociclib), fulvestrant",,,,,,,,doc:hc.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [product monograph]. HC.,Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.,Pfizer Canada ULC,Ibrance,palbociclib,2016-03-15,2025-06-12,2025-03-24,https://pdf.hres.ca/dpd_pm/00080011.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,145,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2057,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.iclusig:0,"ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance",,,"Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.",T315I mutation positive,chronic myeloid leukemia (CML),Iclusig (ponatinib),,,,,,,,doc:hc.iclusig,Document,Regulatory approval,Iclusig (ponatinib) [product monograph]. HC.,"Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.","Takeda Pharmaceuticals U.S.A., Inc.",Iclusig,ponatinib,2015-03-31,2025-06-12,2025-02-24,https://pdf.hres.ca/dpd_pm/00078669.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,363,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 32, 'name': 'ABL1 p.T315I', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '5'}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],43,,,Drug,Ponatinib,ncit:C95777,C95777,Ponatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2058,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.iclusig:1,"ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including Ph+ ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance",,,"Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.","Philadelphia chromosome positive, T315I mutation positive",acute lymphoblastic leukemia (Ph+ ALL),Iclusig (ponatinib),,,,,,,,doc:hc.iclusig,Document,Regulatory approval,Iclusig (ponatinib) [product monograph]. HC.,"Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.","Takeda Pharmaceuticals U.S.A., Inc.",Iclusig,ponatinib,2015-03-31,2025-06-12,2025-02-24,https://pdf.hres.ca/dpd_pm/00078669.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,362,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}, {'id': 32, 'name': 'ABL1 p.T315I', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '5'}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],43,,,Drug,Ponatinib,ncit:C95777,C95777,Ponatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2059,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.imfinzi:0,IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,,,Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,"Imfinzi (durvalumab), tremelimumab, platinum-based chemotherapy",,,,,,,,doc:hc.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [product monograph]. HC.,AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Imfinzi,durvalumab,2017-11-03,2025-06-12,2025-04-10,https://pdf.hres.ca/dpd_pm/00080178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,585,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],117,AND,"[{'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2060,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.imfinzi:1,"Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",,,"Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",mismatch repair deficient (dMMR),primary advanced or recurrent endometrial cancer,"Imfinzi (durvalumab), carboplatin, paclitaxel",,,,,,,,doc:hc.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [product monograph]. HC.,AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Imfinzi,durvalumab,2017-11-03,2025-06-12,2025-04-10,https://pdf.hres.ca/dpd_pm/00080178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,109,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],25,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2061,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.iressa:0,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,,,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,activating mutations of EGFR,locally advanced or metastatic non-small cell lung cancer (NSCLC),Iressa (gefitinib),,,,,,,,doc:hc.iressa,Document,Regulatory approval,Iressa (gefitinib) [product monograph]. HC.,AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.,AstraZeneca Canada Inc.,Iressa,gefitinib,2003-12-17,2025-06-12,2021-03-31,https://pdf.hres.ca/dpd_pm/00060650.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,147,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],33,,,Drug,Gefitinib,ncit:C1855,C1855,Gefitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2062,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.iressa:0,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,,,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,activating mutations of EGFR,locally advanced or metastatic non-small cell lung cancer (NSCLC),Iressa (gefitinib),,,,,,,,doc:hc.iressa,Document,Regulatory approval,Iressa (gefitinib) [product monograph]. HC.,AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.,AstraZeneca Canada Inc.,Iressa,gefitinib,2003-12-17,2025-06-12,2021-03-31,https://pdf.hres.ca/dpd_pm/00060650.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,148,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],33,,,Drug,Gefitinib,ncit:C1855,C1855,Gefitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2063,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.iressa:0,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,,,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,activating mutations of EGFR,locally advanced or metastatic non-small cell lung cancer (NSCLC),Iressa (gefitinib),,,,,,,,doc:hc.iressa,Document,Regulatory approval,Iressa (gefitinib) [product monograph]. HC.,AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.,AstraZeneca Canada Inc.,Iressa,gefitinib,2003-12-17,2025-06-12,2021-03-31,https://pdf.hres.ca/dpd_pm/00060650.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,559,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 19, 'name': 'EGFR oncogenic variants', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],33,,,Drug,Gefitinib,ncit:C1855,C1855,Gefitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2064,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.itovebi:0,"ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",,,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","PIK3CA-mutated, HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Itovebi (inavolisib), palbociclib, fulvestrant",,,,,,,,doc:hc.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [product monograph]. HC.,Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Itovebi,inavolisib,2025-02-14,2025-06-12,2025-02-14,https://pdf.hres.ca/dpd_pm/00078611.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,510,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2065,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.itovebi:0,"ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",,,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","PIK3CA-mutated, HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Itovebi (inavolisib), palbociclib, fulvestrant",,,,,,,,doc:hc.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [product monograph]. HC.,Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Itovebi,inavolisib,2025-02-14,2025-06-12,2025-02-14,https://pdf.hres.ca/dpd_pm/00078611.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,511,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2066,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.itovebi:0,"ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",,,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","PIK3CA-mutated, HR-positive, HER2-negative",locally advanced or metastatic breast cancer,"Itovebi (inavolisib), palbociclib, fulvestrant",,,,,,,,doc:hc.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [product monograph]. HC.,Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Itovebi,inavolisib,2025-02-14,2025-06-12,2025-02-14,https://pdf.hres.ca/dpd_pm/00078611.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,512,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2067,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.jemperli:0,JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,,,Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,"mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)",recurrent or advanced endometrial cancer,Jemperli (dostarlimab),,,,,,,,doc:hc.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [product monograph]. HC.,GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.,GlaxoSmithKline Inc.,Jemperli,dostarlimab,2025-04-06,2025-06-12,2025-04-16,https://pdf.hres.ca/dpd_pm/00080289.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,102,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],47,,,Drug,Dostarlimab,ncit:C126799,C126799,Dostarlimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2068,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.jemperli:0,JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,,,Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,"mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)",recurrent or advanced endometrial cancer,Jemperli (dostarlimab),,,,,,,,doc:hc.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [product monograph]. HC.,GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.,GlaxoSmithKline Inc.,Jemperli,dostarlimab,2025-04-06,2025-06-12,2025-04-16,https://pdf.hres.ca/dpd_pm/00080289.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,587,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],47,,,Drug,Dostarlimab,ncit:C126799,C126799,Dostarlimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2069,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kadcyla:0,"KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.",,,"Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.",HER2-positive,metastatic breast cancer,Kadcyla (trastuzumab emtansine),,,,,,,,doc:hc.kadcyla,Document,Regulatory approval,Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.,Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Kadcyla,ado-trastuzumab emtansine,2013-09-11,2025-06-12,2022-10-13,https://pdf.hres.ca/dpd_pm/00067729.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,20,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],52,,,Drug,Trastuzumab emtansine,ncit:C82492,C82492,Trastuzumab Emtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2070,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kadcyla:1,KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.,,,Health Canada approved trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.,HER2-positive,early breast cancer,Kadcyla (trastuzumab emtansine),,,,,,,,doc:hc.kadcyla,Document,Regulatory approval,Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.,Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Kadcyla,ado-trastuzumab emtansine,2013-09-11,2025-06-12,2022-10-13,https://pdf.hres.ca/dpd_pm/00067729.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,20,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],52,,,Drug,Trastuzumab emtansine,ncit:C82492,C82492,Trastuzumab Emtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2071,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:0,"KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",,,"Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",BRAF V600 mutation,unresectable or metastatic melanoma,Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,843,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2072,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:0,"KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",,,"Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",BRAF V600 mutation,unresectable or metastatic melanoma,Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,844,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2073,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:1,"KEYTRUDA (pembrolizumab) as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.",,,"Health Canada approved pembrolizumab for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.","PD-L1 (TPS  1%), EGFR genomic tumour aberrations, ALK genomic tumour aberrations",metastatic non-small cell lung carcinoma (NSCLC),Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,318,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2074,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:3,KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.,,,Health Canada approved pembrolizumab as a monotherapy for treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.,PD-L1 (TPS  1%),metastatic non-small cell lung cancer (NSCLC),Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,319,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2075,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:4,"KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",,,Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.,MSI-H or dMMR,metastatic colorectal cancer (CRC),Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,323,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2076,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:4,"KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",,,Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.,MSI-H or dMMR,metastatic colorectal cancer (CRC),Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,324,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2077,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:5,"KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",,,,MSI-H or dMMR ,unresectable or metastatic MSI-H or dMMR solid tumors,Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,321,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2078,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:5,"KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",,,,MSI-H or dMMR ,unresectable or metastatic MSI-H or dMMR solid tumors,Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,322,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2079,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:7,"KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.",, ,"Health Canada approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.",PD-L1 (CPS  1), metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC),Keytruda (pembrolizumab),,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,320,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",25,Disease,Head and Neck Squamous Cell Carcinoma,oncotree:HNSC,HNSC,Head and Neck Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2080,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:8,"KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.","HER2-positive, PD-L1 (CPS  1)", locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma,"Keytruda (pembrolizumab), trastuzumab, fluoropyrimidine, platinum-containing chemotherapy",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,325,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],53,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2081,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:9,"KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",,,"Health Canada approved pembrolizumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.,"Keytruda (pembrolizumab), fluoropyrimidine, platinum-containing chemotherapy",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,327,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],55,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2082,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:10,"KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.",PD-L1 (CPS) >= 10,locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC),"Keytruda (pembrolizumab), chemotherapy",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,346,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 41, 'name': 'PD-L1 (CPS) >= 10', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '10'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],63,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2083,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:11,"KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",PD-L1 (CPS  1),"persistent, recurrent, or metastatic cervical cancer","Keytruda (pembrolizumab), chemotherapy, bevacizumab",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,333,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],58,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2084,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:11,"KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",PD-L1 (CPS  1),"persistent, recurrent, or metastatic cervical cancer","Keytruda (pembrolizumab), chemotherapy, bevacizumab",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,334,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],58,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2085,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:11,"KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",PD-L1 (CPS  1),"persistent, recurrent, or metastatic cervical cancer","Keytruda (pembrolizumab), chemotherapy, bevacizumab",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,337,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],60,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2086,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.keytruda:11,"KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",,,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.",PD-L1 (CPS  1),"persistent, recurrent, or metastatic cervical cancer","Keytruda (pembrolizumab), chemotherapy, bevacizumab",,,,,,,,doc:hc.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [product monograph]. HC.,Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.,Merck Canada Inc.,Keytruda,pembrolizumab,2025-04-11,2025-06-12,2025-04-11,https://pdf.hres.ca/dpd_pm/00080285.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,338,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],60,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2087,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,372,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2088,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,373,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2089,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,374,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2090,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,375,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2091,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,376,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2092,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:0,"KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",,,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), aromatase inhibitor",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,377,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2093,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:1,"KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",,,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), fulvestrant",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,140,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2094,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:1,"KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",,,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), fulvestrant",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,141,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2095,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.kisqali:1,"KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",,,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,"Kisqali (ribociclib), fulvestrant",,,,,,,,doc:hc.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Kisqali,ribociclib,2018-03-02,2025-06-12,2024-05-31,https://pdf.hres.ca/dpd_pm/00075798.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,142,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2096,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lazcluze:0,LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,,,Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,EGFR exon 19 deletions or exon 21 L858R,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Lazcluze (lazertinib), amivantamab",,,,,,,,doc:hc.lazcluze,Document,Regulatory approval,Lazcluze (lazertinib) [product monograph]. HC.,Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.,Janssen Inc.,Lazcluze,lazertinib,2025-03-06,2025-06-12,2025-03-06,https://pdf.hres.ca/dpd_pm/00078792.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,463,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2097,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lazcluze:0,LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,,,Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,EGFR exon 19 deletions or exon 21 L858R,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Lazcluze (lazertinib), amivantamab",,,,,,,,doc:hc.lazcluze,Document,Regulatory approval,Lazcluze (lazertinib) [product monograph]. HC.,Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.,Janssen Inc.,Lazcluze,lazertinib,2025-03-06,2025-06-12,2025-03-06,https://pdf.hres.ca/dpd_pm/00078792.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,464,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2098,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.libtayo:0,"LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",,,"Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.","PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",non-small cell lung cancer (NSCLC),Libtayo (Cemiplimab),,,,,,,,doc:hc.libtayo,Document,Regulatory approval,Libtayo (cemiplimab) [product monograph]. HC.,Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.,Regeneron Canada Company,Libtayo,cemiplimab,2019-04-10,2025-06-12,2025-01-30,https://pdf.hres.ca/dpd_pm/00078455.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,618,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 46, 'name': 'Wild type ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 39, 'name': 'PD-L1 >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.5'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],55,,,Drug,Cemiplimab,ncit:C121540,C121540,Cemiplimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2099,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.libtayo:0,"LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",,,"Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.","PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",non-small cell lung cancer (NSCLC),Libtayo (Cemiplimab),,,,,,,,doc:hc.libtayo,Document,Regulatory approval,Libtayo (cemiplimab) [product monograph]. HC.,Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.,Regeneron Canada Company,Libtayo,cemiplimab,2019-04-10,2025-06-12,2025-01-30,https://pdf.hres.ca/dpd_pm/00078455.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,75,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 46, 'name': 'Wild type ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],13,AND,"[{'id': 55, 'conceptType': 'Drug', 'name': 'Cemiplimab', 'primaryCoding': {'id': 'ncit:C121540', 'code': 'C121540', 'name': 'Cemiplimab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2100,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lorbrena:0,LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,,,Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,ALK-positive,locally advanced or metastatic non-small cell lung cancer (NSCLC),Lorbrena (lorlatinib),,,,,,,,doc:hc.lorbrena,Document,Regulatory approval,Lorbrena (lorlatinib) [product monograph]. HC.,Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.,Pfizer Canada ULC,Lorbrena,lorlatinib,2019-02-20,2025-06-13,2024-10-28,https://pdf.hres.ca/dpd_pm/00077541.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,203,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],56,,,Drug,Lorlatinib,ncit:C113655,C113655,Lorlatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113655'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2101,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lorbrena:1,"LORBRENA (lorlatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.",,,"Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.",ALK-positive,metastatic non-small cell lung cancer (NSCLC),Lorbrena (lorlatinib),,,,,,,,doc:hc.lorbrena,Document,Regulatory approval,Lorbrena (lorlatinib) [product monograph]. HC.,Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.,Pfizer Canada ULC,Lorbrena,lorlatinib,2019-02-20,2025-06-13,2024-10-28,https://pdf.hres.ca/dpd_pm/00077541.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,203,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],56,,,Drug,Lorlatinib,ncit:C113655,C113655,Lorlatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113655'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2102,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lumakras', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lumakras (sotorasib) [product monograph]. HC.', 'citation': 'Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Lumakras', 'drug_name_generic': 'sotorasib', 'first_published': '2021-09-09', 'access_date': '2025-06-12', 'publication_date': '2025-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00078781.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lumakras:0,LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.,,,Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.,KRAS p.G12C,locally advanced or metastatic non-small cell lung cancer (NSCLC),Lumakras (sotorasib),,,,,,,,doc:hc.lumakras,Document,Regulatory approval,Lumakras (sotorasib) [product monograph]. HC.,Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.,Amgen Canada Inc.,Lumakras,sotorasib,2021-09-09,2025-06-12,2025-03-04,https://pdf.hres.ca/dpd_pm/00078781.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,411,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 45, 'name': 'KRAS p.G12C', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],57,,,Drug,Sotorasib,ncit:C154287,C154287,Sotorasib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C154287'],[],"[{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2103,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:0,"LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.","deleterious or suspected deleterious gBRCAm, HER2-negative",high risk early breast cancer,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,258,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2104,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:0,"LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.","deleterious or suspected deleterious gBRCAm, HER2-negative",high risk early breast cancer,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,259,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2105,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:1,"LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.","deleterious or suspected deleterious gBRCAm, HER2-negative",metastatic breast cancer,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,258,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2106,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:1,"LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.","deleterious or suspected deleterious gBRCAm, HER2-negative",metastatic breast cancer,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,259,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2107,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,231,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2108,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,232,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2109,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,233,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2110,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,234,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2111,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,235,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2112,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,236,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2113,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,237,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2114,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,238,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2115,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,239,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2116,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,240,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2117,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,241,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2118,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:2,"LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",BRCA-mutated,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,242,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2119,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,243,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2120,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,244,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2121,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,245,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2122,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,246,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2123,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,248,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2124,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,249,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2125,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,250,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2126,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,251,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2127,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,253,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2128,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,254,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2129,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,255,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2130,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:3,"LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",,,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer","Lynparza (olaparib), bevacizumab",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,256,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2131,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:4,LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.,deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),metastatic adenocarcinoma of the pancreas,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,260,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",52,Disease,Pancreatic Adenocarcinoma,oncotree:PAAD,PAAD,Pancreatic Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2132,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:4,LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.,deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),metastatic adenocarcinoma of the pancreas,Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,261,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",52,Disease,Pancreatic Adenocarcinoma,oncotree:PAAD,PAAD,Pancreatic Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2133,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,263,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2134,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,264,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2135,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,265,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2136,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,266,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2137,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,267,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 104, 'name': 'ATM pathogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2138,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:5,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation, metastatic castrationresistant Prostate Cancer (mCRPC),Lynparza (olaparib),,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,268,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 105, 'name': 'ATM oncogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2139,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,291,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2140,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,292,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2141,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,293,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2142,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,294,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2143,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,295,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2144,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,296,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2145,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,297,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2146,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.lynparza:6,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,,,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,germline and/or somatic BRCA mutation,metastatic castration-resistant prostate cancer (mCRPC),"Lynparza (olaparib), abiraterone, prednisone or prednisolone",,,,,,,,doc:hc.lynparza,Document,Regulatory approval,Lynparza (olaparib) [product monograph]. HC.,AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Lynparza,olaparib,2025-04-29,2025-06-12,2025-04-29,https://pdf.hres.ca/dpd_pm/00080379.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,298,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2147,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mekinist:0,"MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",,,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.",BRAF V600E or V600K mutation,unresectable or metastatic melanoma,Mekinist (trametinib) monotherapy or dabrafenib,,,,,,,,doc:hc.mekinist,Document,Regulatory approval,Mekinist (trametinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Mekinist,trametinib,2013-07-18,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077955.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,417,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],66,,,Drug,Trametinib,ncit:C77908,C77908,Trametinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908'],[],"[{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2148,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mekinist:0,"MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",,,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.",BRAF V600E or V600K mutation,unresectable or metastatic melanoma,Mekinist (trametinib) monotherapy or dabrafenib,,,,,,,,doc:hc.mekinist,Document,Regulatory approval,Mekinist (trametinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Mekinist,trametinib,2013-07-18,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077955.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,416,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],66,,,Drug,Trametinib,ncit:C77908,C77908,Trametinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908'],[],"[{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2149,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mekinist:2,MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,,,Health Canada approved trametinib in combination with dabrafenib for the treatment of patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).,BRAF V600E mutation,metastatic non-small cell lung cancer (NSCLC),"Mekinist (trametinib), dabrafenib",,,,,,,,doc:hc.mekinist,Document,Regulatory approval,Mekinist (trametinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Mekinist,trametinib,2013-07-18,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077955.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,91,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2150,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mekinist:3,MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,,,Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant low-grade glioma (LGG) requiring systemic therapy.,BRAF V600E mutation,low-grade glioma (LGG),"Mekinist (trametinib), dabrafenib",,,,,,,,doc:hc.mekinist,Document,Regulatory approval,Mekinist (trametinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Mekinist,trametinib,2013-07-18,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077955.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,94,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2151,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mekinist:0,"MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",,,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.",BRAF V600E or V600K mutation,unresectable or metastatic melanoma,Mekinist (trametinib) monotherapy or dabrafenib,,,,,,,,doc:hc.mekinist,Document,Regulatory approval,Mekinist (trametinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Mekinist,trametinib,2013-07-18,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077955.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,660,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",83,Disease,"High-Grade Glioma, NOS",oncotree:HGGNOS,HGGNOS,"High-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2152,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': '2021-03-02', 'access_date': '2025-06-13', 'publication_date': '2021-03-02', 'url': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mektovi:0,"MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",,,"Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",BRAF V600E or V600K,unresectable or metastatic melanoma ,"Mektovi (binimetinib), encorafenib",,,,,,,,doc:hc.mektovi,Document,Regulatory approval,Mektovi (binimetinib) [product monograph]. HC.,Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.,Pfizer Canada ULC,Mektovi,binimetinib,2021-03-02,2025-06-13,2021-03-02,https://pdf.hres.ca/dpd_pm/00060288.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,41,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2153,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': '2021-03-02', 'access_date': '2025-06-13', 'publication_date': '2021-03-02', 'url': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mektovi:0,"MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",,,"Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",BRAF V600E or V600K,unresectable or metastatic melanoma ,"Mektovi (binimetinib), encorafenib",,,,,,,,doc:hc.mektovi,Document,Regulatory approval,Mektovi (binimetinib) [product monograph]. HC.,Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.,Pfizer Canada ULC,Mektovi,binimetinib,2021-03-02,2025-06-13,2021-03-02,https://pdf.hres.ca/dpd_pm/00060288.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,42,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2154,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.mylotarg', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Mylotarg (gemtuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00069427.PDF. Revised February 2023. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mylotarg', 'drug_name_generic': 'gemtuzumab ozogamicin', 'first_published': '2019-11-28', 'access_date': '2025-06-13', 'publication_date': '2023-02-02', 'url': 'https://pdf.hres.ca/dpd_pm/00069427.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98440', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.mylotarg:0,"Mylotarg (gemtuzumab ozogamicin for injection) is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.",,,"Health Canada approved gemtuzumab ozogamicin  in combination with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.",CD33-positive,acute myeloid leukeia (AML),"Mylotarg (gemtuzumab ozogamicin), daunorubicin (DNR), cytarabine (AraC)",,,,,,,,doc:hc.mylotarg,Document,Regulatory approval,Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC.,Pfizer Canada ULC. Mylotarg (gemtuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00069427.PDF. Revised February 2023. Accessed June 2025.,Pfizer Canada ULC,Mylotarg,gemtuzumab ozogamicin,2019-11-28,2025-06-13,2023-02-02,https://pdf.hres.ca/dpd_pm/00069427.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98440,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,628,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 55, 'name': 'CD33 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD33'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,AND,"[{'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 69, 'conceptType': 'Drug', 'name': 'Gemtuzumab ozogamicin', 'primaryCoding': {'id': 'ncit:C1806', 'code': 'C1806', 'name': 'Gemtuzumab Ozogamicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1806']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD33 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2155,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.nerlynx:0,"NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",,,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","HR+, HER2-overexpressed/amplified",early-stage breast cancer,Nerlynx (neratinib),,,,,,,,doc:hc.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [product monograph]. HC.,Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.,Knight Therapeutics Inc.,Nerlynx,neratinib,2019-07-15,2025-06-13,2021-07-16,https://pdf.hres.ca/dpd_pm/00062158.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,629,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,,,Drug,Neratinib,ncit:C49094,C49094,Neratinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2156,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.nerlynx:0,"NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",,,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","HR+, HER2-overexpressed/amplified",early-stage breast cancer,Nerlynx (neratinib),,,,,,,,doc:hc.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [product monograph]. HC.,Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.,Knight Therapeutics Inc.,Nerlynx,neratinib,2019-07-15,2025-06-13,2021-07-16,https://pdf.hres.ca/dpd_pm/00062158.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,630,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,,,Drug,Neratinib,ncit:C49094,C49094,Neratinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2157,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.nerlynx:0,"NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",,,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","HR+, HER2-overexpressed/amplified",early-stage breast cancer,Nerlynx (neratinib),,,,,,,,doc:hc.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [product monograph]. HC.,Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.,Knight Therapeutics Inc.,Nerlynx,neratinib,2019-07-15,2025-06-13,2021-07-16,https://pdf.hres.ca/dpd_pm/00062158.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,631,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,,,Drug,Neratinib,ncit:C49094,C49094,Neratinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2158,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.nerlynx:1,"NERLYNX (neratinib) is indicated in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.",,,"Health Canada approved neratinib in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.",HER2-overexpressed/amplified,metastatic breast cancer,"Nerlynx (neratinib), capecitabine",,,,,,,,doc:hc.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [product monograph]. HC.,Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.,Knight Therapeutics Inc.,Nerlynx,neratinib,2019-07-15,2025-06-13,2021-07-16,https://pdf.hres.ca/dpd_pm/00062158.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,220,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],41,AND,"[{'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primaryCoding': {'id': 'ncit:C49094', 'code': 'C49094', 'name': 'Neratinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2159,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:0,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",,,"Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.","BRAF V600 mutation-positive,", unresectable or metastatic melanoma,Opdivo (nivolumab),,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,845,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],72,,,Drug,Nivolumab,ncit:C68814,C68814,Nivolumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2160,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:0,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",,,"Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.","BRAF V600 mutation-positive,", unresectable or metastatic melanoma,Opdivo (nivolumab),,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,846,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],72,,,Drug,Nivolumab,ncit:C68814,C68814,Nivolumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2161,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:2,"OPDIVO (nivolumab) in combination with ipilimumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",,,"Health Canada approved nivolumab in combination with ipilimumab, for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.", PD-L1  1% with no EGFR or ALK genomic tumour aberrations,metastatic non-small cell lung cancer (NSCLC),"Opdivo (nivolumab), ipilimumab",,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,171,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2162,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:6,"OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",,,"Health Canada approved nivolumab, in combination with ipilimuab, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",PD-L1  1%,unresectable or metastatic esophageal squamous cell carcinoma (ESCC),"Opdivo (nivolumab), ipilimumab",,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,642,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",82,Disease,Esophageal Squamous Cell Carcinoma,oncotree:ESCC,ESCC,Esophageal Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2163,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:7,"OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",,,"Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",PD-L1  1%,unresectable or metastatic esophageal squamous cell carcinoma (ESCC),"Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy",,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,643,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",82,Disease,Esophageal Squamous Cell Carcinoma,oncotree:ESCC,ESCC,Esophageal Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC'],[],128,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2164,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.opdivo:7,"OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",,,"Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",PD-L1  1%,unresectable or metastatic esophageal squamous cell carcinoma (ESCC),"Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy",,,,,,,,doc:hc.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Opdivo,nivolumab,2015-09-25,2025-06-13,2024-06-28,https://pdf.hres.ca/dpd_pm/00076152.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,800,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",82,Disease,Esophageal Squamous Cell Carcinoma,oncotree:ESCC,ESCC,Esophageal Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC'],[],129,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2165,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [product monograph]. HC.', 'citation': 'Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.', 'company': 'Incyte Corporation', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': '2021-09-09', 'access_date': '2025-06-13', 'publication_date': '2021-09-08', 'url': 'https://pdf.hres.ca/dpd_pm/00062968.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.pemazyre:0,"PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",,,"Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",FGFR2 fusion or rearrangement,unresectable locally advanced or metastatic cholangiocarcinoma,Pemazyre (pemigatinib),,,,,,,,doc:hc.pemazyre,Document,Regulatory approval,Pemazyre (pemigatinib) [product monograph]. HC.,Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.,Incyte Corporation,Pemazyre,pemigatinib,2021-09-09,2025-06-13,2021-09-08,https://pdf.hres.ca/dpd_pm/00062968.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,348,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 52, 'name': 'FGFR2::v', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],133,,,Drug,Pemigatinib,ncit:C121553,C121553,Pemigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121553'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2166,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [product monograph]. HC.', 'citation': 'Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.', 'company': 'Incyte Corporation', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': '2021-09-09', 'access_date': '2025-06-13', 'publication_date': '2021-09-08', 'url': 'https://pdf.hres.ca/dpd_pm/00062968.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.pemazyre:0,"PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",,,"Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",FGFR2 fusion or rearrangement,unresectable locally advanced or metastatic cholangiocarcinoma,Pemazyre (pemigatinib),,,,,,,,doc:hc.pemazyre,Document,Regulatory approval,Pemazyre (pemigatinib) [product monograph]. HC.,Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.,Incyte Corporation,Pemazyre,pemigatinib,2021-09-09,2025-06-13,2021-09-08,https://pdf.hres.ca/dpd_pm/00062968.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,349,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 53, 'name': 'FGFR2 rearrangements', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],133,,,Drug,Pemigatinib,ncit:C121553,C121553,Pemigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121553'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2167,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2168,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2169,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2170,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,354,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],68,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2171,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,355,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],69,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2172,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,356,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2173,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,357,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],71,AND,"[{'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2174,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,358,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],72,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2175,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,359,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],73,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2176,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,360,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],74,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2177,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,759,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],154,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2178,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,764,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],157,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2179,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:0,"PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,early stage breast cancer,"Perjeta (pertuzumab), trastuzumab, chemotherapy",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,765,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],158,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 117, 'conceptType': 'Drug', 'name': 'Vinorelbine', 'primaryCoding': {'id': 'ncit:C1275', 'code': 'C1275', 'name': 'Vinorelbine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1275']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2180,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.perjeta:1,PERJETA (pertuzumab) is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,,,Health Canada approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,HER2-positive,metastatic breast cancer,"Perjeta (pertuzumab), trastuzumab, docetaxel",,,,,,,,doc:hc.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.,Hoffmann-La Roche Limited,Perjeta,pertuzumab,2013-04-12,2025-06-13,2013-04-12,https://pdf.hres.ca/dpd_pm/00060125.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2181,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2182,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2183,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2184,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,354,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],68,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2185,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,355,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],69,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2186,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,356,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2187,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,357,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],71,AND,"[{'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2188,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,358,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],72,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2189,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,359,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],73,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2190,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,360,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],74,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2191,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,759,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],154,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2192,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,764,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],157,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2193,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:0,"PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",,,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer","Phesgo (pertuzumab and trastuzumab), chemotherapy",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,765,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],158,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 117, 'conceptType': 'Drug', 'name': 'Vinorelbine', 'primaryCoding': {'id': 'ncit:C1275', 'code': 'C1275', 'name': 'Vinorelbine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1275']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2194,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.phesgo:2,"PHESGO (pertuzumab and trastuzumab), is indicated in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",,,"Health Canada approved pertuzumab and trastuzumab in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anit-HER2 therapy or chemotherapy for metastatic disease.",HER2-positive,metastatic breast cancer,"Phesgo (pertuzumab and trastuzumab), docetaxel",,,,,,,,doc:hc.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.,Hoffmann-La Roche Limited,Phesgo,pertuzumab and trastuzumab,2021-03-01,2025-06-13,2022-01-05,https://pdf.hres.ca/dpd_pm/00064237.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2195,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.retevmo:0,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,,,Health Canada approved selpercatinib as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,RET fusion-positive,metastatic non-small cell lung cancer (NSCLC),Retevmo (selpercatinib),,,,,,,,doc:hc.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [product monograph]. HC.,Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.,Loxo Oncology Inc.,Retevmo,selpercatinib,2021-06-11,2025-06-13,2025-01-10,https://pdf.hres.ca/dpd_pm/00078253.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,407,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2196,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.retevmo:1,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,,,Health Canada approved selpercatinib as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,RET-mutant,unresectable advanced or metastatic medullary thyroid cancer (MTC),Retevmo (selpercatinib),,,,,,,,doc:hc.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [product monograph]. HC.,Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.,Loxo Oncology Inc.,Retevmo,selpercatinib,2021-06-11,2025-06-13,2025-01-10,https://pdf.hres.ca/dpd_pm/00078253.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,408,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 152, 'name': 'RET oncogenic variants', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'requires_oncogenic', 'value': True}]}]",38,Disease,Medullary Thyroid Cancer,oncotree:THME,THME,Medullary Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THME'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2197,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.retevmo:2,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.,,,Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.,RET fusion-positive,advanced or metastatic differentiated thyroid carcinoma,Retevmo (selpercatinib),,,,,,,,doc:hc.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [product monograph]. HC.,Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.,Loxo Oncology Inc.,Retevmo,selpercatinib,2021-06-11,2025-06-13,2025-01-10,https://pdf.hres.ca/dpd_pm/00078253.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,656,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",75,Disease,Papillary Thyroid Cancer,oncotree:THPA,THPA,Papillary Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THPA'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2198,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.revlimid', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revlimid (lenalidomide) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Revlimid', 'drug_name_generic': 'lenalidomide', 'first_published': '2024-02-09', 'access_date': '2025-06-13', 'publication_date': '2024-02-09', 'url': 'https://pdf.hres.ca/dpd_pm/00074535.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.revlimid:0,REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.,,,Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.,5q deletion,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes,Revlimid (lenalidomide),,,,,,,,doc:hc.revlimid,Document,Regulatory approval,Revlimid (lenalidomide) [product monograph]. HC.,Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.,Bristol-Myers Squibb Canada,Revlimid,lenalidomide,2024-02-09,2025-06-13,2024-02-09,https://pdf.hres.ca/dpd_pm/00074535.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,202,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 61, 'name': '5q deletion', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number (arm level)'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '5'}, {'name': 'direction', 'value': 'Deletion'}, {'name': 'arm', 'value': 'q'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],79,,,Drug,Lenalidomide,ncit:C2668,C2668,Lenalidomide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2668'],[],"[{'name': 'therapy_strategy', 'value': ['Angiogenesis inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2199,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rituxan:0,"RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.",,,"Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.",CD20 positive,relapsed or refractory low-grade or follicular B-cell non-Hodgkins lymphoma,RITUXAN (rituximab for injection),,,,,,,,doc:hc.rituxan,Document,Regulatory approval,Rituxan (rituximab) [product monograph]. HC.,Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rituxan,rituximab,2000-03-17,2025-06-13,2023-06-02,https://pdf.hres.ca/dpd_pm/00071131.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,378,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],60,,,Drug,Rituximab,ncit:C1702,C1702,Rituximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702'],[],"[{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2200,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rituxan:0,"RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.",,,"Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.",CD20 positive,relapsed or refractory low-grade or follicular B-cell non-Hodgkins lymphoma,RITUXAN (rituximab for injection),,,,,,,,doc:hc.rituxan,Document,Regulatory approval,Rituxan (rituximab) [product monograph]. HC.,Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rituxan,rituximab,2000-03-17,2025-06-13,2023-06-02,https://pdf.hres.ca/dpd_pm/00071131.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,822,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],60,,,Drug,Rituximab,ncit:C1702,C1702,Rituximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702'],[],"[{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2201,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rituxan:1,"RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.",,,"Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP chemotherapy.",CD20 positive,diffuse large B-cell non-Hodgkins lymphoma (DLBCL),"RITUXAN (rituximab for injection), CHOP chemotherapy",,,,,,,,doc:hc.rituxan,Document,Regulatory approval,Rituxan (rituximab) [product monograph]. HC.,Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rituxan,rituximab,2000-03-17,2025-06-13,2023-06-02,https://pdf.hres.ca/dpd_pm/00071131.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,383,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",77,Disease,Diffuse Large B-Cell Lymphoma,oncotree:DLBCLNOS,DLBCLNOS,Diffuse Large B-Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2202,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rituxan:1,"RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.",,,"Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP chemotherapy.",CD20 positive,diffuse large B-cell non-Hodgkins lymphoma (DLBCL),"RITUXAN (rituximab for injection), CHOP chemotherapy",,,,,,,,doc:hc.rituxan,Document,Regulatory approval,Rituxan (rituximab) [product monograph]. HC.,Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rituxan,rituximab,2000-03-17,2025-06-13,2023-06-02,https://pdf.hres.ca/dpd_pm/00071131.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,622,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",77,Disease,Diffuse Large B-Cell Lymphoma,oncotree:DLBCLNOS,DLBCLNOS,Diffuse Large B-Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS'],[],124,AND,"[{'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2203,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rituxan:2,"RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.",,,"Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.",CD20 positive,Stage III/IV follicular B-cell non-Hodgkin's lymphoma,"RITUXAN (rituximab for injection), CVP chemotherapy",,,,,,,,doc:hc.rituxan,Document,Regulatory approval,Rituxan (rituximab) [product monograph]. HC.,Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rituxan,rituximab,2000-03-17,2025-06-13,2023-06-02,https://pdf.hres.ca/dpd_pm/00071131.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,818,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],178,AND,"[{'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2204,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rozlytrek:0,"ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",,,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",NTRK gene fusion,unresectable locally advanced or metastatic extracranial solid tumours,Rozlytrek (entrectinib),,,,,,,,doc:hc.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rozlytrek,entrectinib,2020-02-07,2025-06-13,2023-11-09,https://pdf.hres.ca/dpd_pm/00073345.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,121,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 63, 'name': 'v::NTRK1', 'genes': [{'id': 35, 'name': 'NTRK1', 'primaryCoding': {'id': 'hgnc:8031', 'code': 'HGNC:8031', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002529.4', 'code': 'NM_002529.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000198400', 'code': 'ENSG00000198400', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000198400']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4914', 'code': '4914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4914']}}], 'extensions': [{'name': 'location', 'value': '1q23.1'}, {'name': 'location_sortable', 'value': '01q23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2205,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rozlytrek:0,"ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",,,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",NTRK gene fusion,unresectable locally advanced or metastatic extracranial solid tumours,Rozlytrek (entrectinib),,,,,,,,doc:hc.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rozlytrek,entrectinib,2020-02-07,2025-06-13,2023-11-09,https://pdf.hres.ca/dpd_pm/00073345.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,122,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 64, 'name': 'v::NTRK2', 'genes': [{'id': 36, 'name': 'NTRK2', 'primaryCoding': {'id': 'hgnc:8032', 'code': 'HGNC:8032', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000148053', 'code': 'ENSG00000148053', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000148053']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4915', 'code': '4915', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4915']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006180.6', 'code': 'NM_006180.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6']}}], 'extensions': [{'name': 'location', 'value': '9q21.33'}, {'name': 'location_sortable', 'value': '09q21.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2206,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rozlytrek:0,"ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",,,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",NTRK gene fusion,unresectable locally advanced or metastatic extracranial solid tumours,Rozlytrek (entrectinib),,,,,,,,doc:hc.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rozlytrek,entrectinib,2020-02-07,2025-06-13,2023-11-09,https://pdf.hres.ca/dpd_pm/00073345.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,123,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 65, 'name': 'v::NTRK3', 'genes': [{'id': 37, 'name': 'NTRK3', 'primaryCoding': {'id': 'hgnc:8033', 'code': 'HGNC:8033', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001012338.3', 'code': 'NM_001012338.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140538', 'code': 'ENSG00000140538', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140538']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4916', 'code': '4916', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4916']}}], 'extensions': [{'name': 'location', 'value': '15q25.3'}, {'name': 'location_sortable', 'value': '15q25.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2207,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rozlytrek:1,ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.,,,Health Canada approved entrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.,ROS1-positive,locally advanced or metastatic non-small cell lung cancer (NSCLC),Rozlytrek (entrectinib),,,,,,,,doc:hc.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [product monograph]. HC.,Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.,Hoffmann-La Roche Limited,Rozlytrek,entrectinib,2020-02-07,2025-06-13,2023-11-09,https://pdf.hres.ca/dpd_pm/00073345.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,120,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2208,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rybrevant:0,"RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",,,"Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Rybrevant (amivantamab), carboplatin, pemetrexed",,,,,,,,doc:hc.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [product monograph]. HC.,Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.,Janssen Inc.,Rybrevant,amivantamab-vmjw,2022-03-30,2025-06-13,2025-01-13,https://pdf.hres.ca/dpd_pm/00078295.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,465,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2209,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rybrevant:0,"RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",,,"Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Rybrevant (amivantamab), carboplatin, pemetrexed",,,,,,,,doc:hc.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [product monograph]. HC.,Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.,Janssen Inc.,Rybrevant,amivantamab-vmjw,2022-03-30,2025-06-13,2025-01-13,https://pdf.hres.ca/dpd_pm/00078295.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,466,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2210,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rybrevant:1,RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.,,,Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.,EGFR Exon 20 insertion mutations,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Rybrevant (amivantamab), carboplatin, pemetrexed",,,,,,,,doc:hc.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [product monograph]. HC.,Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.,Janssen Inc.,Rybrevant,amivantamab-vmjw,2022-03-30,2025-06-13,2025-01-13,https://pdf.hres.ca/dpd_pm/00078295.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,26,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 86, 'name': 'EGFR Exon 20 (Insertion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': '20'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],6,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2211,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rybrevant:2,RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.,,,Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.,EGFR Exon 20 insertion mutations,locally advanced or metastatic non-small cell lung cancer (NSCLC),Rybrevant (amivantamab),,,,,,,,doc:hc.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [product monograph]. HC.,Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.,Janssen Inc.,Rybrevant,amivantamab-vmjw,2022-03-30,2025-06-13,2025-01-13,https://pdf.hres.ca/dpd_pm/00078295.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,27,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 86, 'name': 'EGFR Exon 20 (Insertion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': '20'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],108,,,Drug,Amivantamab,ncit:C124993,C124993,Amivantamab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2212,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,208,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 66, 'name': 'FLT3-ITD', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'requires_oncogenic', 'value': True}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2213,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,209,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 85, 'name': 'FLT3 p.D835Y', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2503G>T'}, {'name': 'protein_change', 'value': 'p.D835Y'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2214,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,210,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 116, 'name': 'FLT3 p.D835A', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2504A>C'}, {'name': 'protein_change', 'value': 'p.D835A'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>G'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2215,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,211,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 117, 'name': 'FLT3 p.D835E', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592640}, {'name': 'end_position', 'value': 28592640}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2505T>G'}, {'name': 'protein_change', 'value': 'p.D835E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913487'}, {'name': 'hgvsg', 'value': '13:g.28592640A>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2216,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,212,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 118, 'name': 'FLT3 p.D835H', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2503G>C'}, {'name': 'protein_change', 'value': 'p.D835H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>G'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2217,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,213,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 119, 'name': 'FLT3 p.D835N', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2503G>A'}, {'name': 'protein_change', 'value': 'p.D835N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2218,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,214,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 120, 'name': 'FLT3 p.D835S', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'TC'}, {'name': 'alternate_allele', 'value': 'CT'}, {'name': 'cdna_change', 'value': 'c.2503_2504delinsAG'}, {'name': 'protein_change', 'value': 'p.D835S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'ENST00000241453.7:c.2503_2504delinsAG'}, {'name': 'hgvsg', 'value': '13:g.28592641_28592642delinsCT'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2219,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,215,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 121, 'name': 'FLT3 p.D835V', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2504A>T'}, {'name': 'protein_change', 'value': 'p.D835V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2220,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,216,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 123, 'name': 'FLT3 p.I836del', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592635}, {'name': 'end_position', 'value': 28592637}, {'name': 'reference_allele', 'value': 'ATG'}, {'name': 'alternate_allele', 'value': '-'}, {'name': 'cdna_change', 'value': 'c.2508_2510del'}, {'name': 'protein_change', 'value': 'p.I836del'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '20'}, {'name': 'hgvsg', 'value': '13:g.28592635_28592637del'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2221,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.rydapt:0,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,,,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,FLT3 mutation,acute myeloid leukemia (AML),"Rydapt (midostaurin), cytarabine, daunorubicin",,,,,,,,doc:hc.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Rydapt,midostaurin,2017-07-21,2025-06-13,2023-03-31,https://pdf.hres.ca/dpd_pm/00070168.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,723,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 66, 'name': 'FLT3-ITD', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'requires_oncogenic', 'value': True}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],149,AND,"[{'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2222,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': '2022-05-19', 'access_date': '2025-06-13', 'publication_date': '2023-06-26', 'url': 'https://pdf.hres.ca/dpd_pm/00071417.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tabrecta:0,TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,,,Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,MET exon 14 skipping, locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC),Tabrecta (capmatinib),,,,,,,,doc:hc.tabrecta,Document,Regulatory approval,Tabrecta (capmatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tabrecta,capmatinib,2022-05-19,2025-06-13,2023-06-26,https://pdf.hres.ca/dpd_pm/00071417.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,73,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 67, 'name': 'MET Exon 14 (Splice Site)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,,,Drug,Capmatinib,ncit:C90564,C90564,Capmatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2223,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': '2022-05-19', 'access_date': '2025-06-13', 'publication_date': '2023-06-26', 'url': 'https://pdf.hres.ca/dpd_pm/00071417.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tabrecta:0,TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,,,Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,MET exon 14 skipping, locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC),Tabrecta (capmatinib),,,,,,,,doc:hc.tabrecta,Document,Regulatory approval,Tabrecta (capmatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tabrecta,capmatinib,2022-05-19,2025-06-13,2023-06-26,https://pdf.hres.ca/dpd_pm/00071417.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,74,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 68, 'name': 'MET Exon 14 (Deletion)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,,,Drug,Capmatinib,ncit:C90564,C90564,Capmatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2224,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tafinlar:0,"TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",,,"Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",unresectable or metastatic melanoma,BRAF V600 mutation,Tafinlar (dabrafenib mesylate),,,,,,,,doc:hc.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tafinlar,dabrafenib,2013-08-23,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077956.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,88,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],67,,,Drug,Dabrafenib,ncit:C82386,C82386,Dabrafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2225,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tafinlar:0,"TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",,,"Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",unresectable or metastatic melanoma,BRAF V600 mutation,Tafinlar (dabrafenib mesylate),,,,,,,,doc:hc.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tafinlar,dabrafenib,2013-08-23,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077956.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,663,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],67,,,Drug,Dabrafenib,ncit:C82386,C82386,Dabrafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2226,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tafinlar:2,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,,,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,BRAF V600E,metastatic non-small cell lung cancer (NSCLC),"Tafinlar (dabrafenib mesylate), trametinib",,,,,,,,doc:hc.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tafinlar,dabrafenib,2013-08-23,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077956.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,91,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2227,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tafinlar:3,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,,,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,BRAF V600E,low-grade glioma (LGG),"Tafinlar (dabrafenib mesylate), trametinib",,,,,,,,doc:hc.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tafinlar,dabrafenib,2013-08-23,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077956.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,94,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2228,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tafinlar:4,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.,,,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.,BRAF V600E,high-grade glioma (HGG),"Tafinalr (dabrafenib mesylate), trametinib",,,,,,,,doc:hc.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tafinlar,dabrafenib,2013-08-23,2025-06-13,2024-12-05,https://pdf.hres.ca/dpd_pm/00077956.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,660,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",83,Disease,"High-Grade Glioma, NOS",oncotree:HGGNOS,HGGNOS,"High-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2229,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:0,TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,stage IB-IIIA1 non-small cell lung cancer (NSCLC),Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2230,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:0,TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,stage IB-IIIA1 non-small cell lung cancer (NSCLC),Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2231,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:1,"TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.",,,"Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.",EGFR exon 19 deletions or exon 21 L858R substitution,"locally advanced, unresectable non-small cell lung cancer (NSCLC)",Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2232,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:1,"TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.",,,"Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.",EGFR exon 19 deletions or exon 21 L858R substitution,"locally advanced, unresectable non-small cell lung cancer (NSCLC)",Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2233,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:2,"TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",,,"Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2234,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:2,"TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",,,"Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2235,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:3,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy",,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,306,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],47,AND,"[{'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2236,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:3,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy",,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,307,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2237,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:3,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy",,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,308,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2238,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:3,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,,,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,EGFR exon 19 deletions or exon 21 L858R substitution,locally advanced or metastatic non-small cell lung cancer (NSCLC),"Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy",,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,309,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],47,AND,"[{'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2239,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tagrisso:4,TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.,,,Health Canada approved osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.,EGFR T790M,locally advanced or metastatic non-small cell lung cancer (NSCLC),Tagrisso (osimertinib),,,,,,,,doc:hc.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [product monograph]. HC.,AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Tagrisso,osimertinib,2016-07-05,2025-06-13,2025-04-23,https://pdf.hres.ca/dpd_pm/00080336.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,310,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 70, 'name': 'EGFR p.T790M', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55249071}, {'name': 'end_position', 'value': 55249071}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2369C>T'}, {'name': 'protein_change', 'value': 'p.T790M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121434569'}, {'name': 'hgvsg', 'value': '7:g.55249071C>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2240,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': '2017-04-12', 'access_date': '2025-06-13', 'publication_date': '2025-01-09', 'url': 'https://pdf.hres.ca/dpd_pm/00078266.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tecentriq:0,"TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on  50% of tumour cells (TCs)",,,Health Canada approved,PD-L1  50%,non-small cell lung cancer (NSCLC),Tecentriq (atezolizumab),,,,,,,,doc:hc.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Tecentriq,atezolizumab,2017-04-12,2025-06-13,2025-01-09,https://pdf.hres.ca/dpd_pm/00078266.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,32,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 39, 'name': 'PD-L1 >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.5'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2241,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': '2017-04-12', 'access_date': '2025-06-13', 'publication_date': '2025-01-09', 'url': 'https://pdf.hres.ca/dpd_pm/00078266.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tecentriq:1,"TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained  50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering  10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",,,"Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained  50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering  10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","PD-L1 >= 50% or PD-L1 >= 10% TIIC, no EGFR or ALK genomic tumour aberrations.",metastatic non-small cell lung cancer (NSCLC),Tecentriq (atezolizumab),,,,,,,,doc:hc.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Tecentriq,atezolizumab,2017-04-12,2025-06-13,2025-01-09,https://pdf.hres.ca/dpd_pm/00078266.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,672,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 39, 'name': 'PD-L1 >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.5'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2242,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': '2017-04-12', 'access_date': '2025-06-13', 'publication_date': '2025-01-09', 'url': 'https://pdf.hres.ca/dpd_pm/00078266.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tecentriq:1,"TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained  50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering  10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",,,"Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained  50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering  10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","PD-L1 >= 50% or PD-L1 >= 10% TIIC, no EGFR or ALK genomic tumour aberrations.",metastatic non-small cell lung cancer (NSCLC),Tecentriq (atezolizumab),,,,,,,,doc:hc.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Tecentriq,atezolizumab,2017-04-12,2025-06-13,2025-01-09,https://pdf.hres.ca/dpd_pm/00078266.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,678,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 73, 'name': 'PD-L1 >= 10% TIIC', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor-infiltrating immune cells (TIIC)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.1'}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2243,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': '2017-04-12', 'access_date': '2025-06-13', 'publication_date': '2025-01-09', 'url': 'https://pdf.hres.ca/dpd_pm/00078266.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tecentriq:5,"TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering  1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.",,,"Health Canada approved atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering  1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.",PD-L1 >= 1%,unresectable locally advanced or metastatic triple-negative breast cancer,"Tecentriq (atezolizumab), nab-paclitaxel",,,,,,,,doc:hc.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [product monograph]. HC.,Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.,Hoffmann-La Roche Limited,Tecentriq,atezolizumab,2017-04-12,2025-06-13,2025-01-09,https://pdf.hres.ca/dpd_pm/00078266.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,679,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],136,AND,"[{'id': 89, 'conceptType': 'Drug', 'name': 'Atezolizumab', 'primaryCoding': {'id': 'ncit:C106250', 'code': 'C106250', 'name': 'Atezolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 51, 'conceptType': 'Drug', 'name': 'Nab-paclitaxel', 'primaryCoding': {'id': 'ncit:C2688', 'code': 'C2688', 'name': 'Nab-paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2244,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tepmetko', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tepmetko (tepotinib) [product monograph]. HC.', 'citation': 'EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.', 'company': 'EMD Serono, a Division of EMD Inc., Canada', 'drug_name_brand': 'Tepmetko', 'drug_name_generic': 'tepotinib', 'first_published': '2021-05-27', 'access_date': '2025-06-13', 'publication_date': '2024-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00074821.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tepmetko:0,TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,,,Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,MET exon 14 skipping,locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC),TEPMETKO (tepotinib),,,,,,,,doc:hc.tepmetko,Document,Regulatory approval,Tepmetko (tepotinib) [product monograph]. HC.,"EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.","EMD Serono, a Division of EMD Inc., Canada",Tepmetko,tepotinib,2021-05-27,2025-06-13,2024-03-04,https://pdf.hres.ca/dpd_pm/00074821.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,414,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 67, 'name': 'MET Exon 14 (Splice Site)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],90,,,Drug,Tepotinib,ncit:C88314,C88314,Tepotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2245,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tepmetko', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tepmetko (tepotinib) [product monograph]. HC.', 'citation': 'EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.', 'company': 'EMD Serono, a Division of EMD Inc., Canada', 'drug_name_brand': 'Tepmetko', 'drug_name_generic': 'tepotinib', 'first_published': '2021-05-27', 'access_date': '2025-06-13', 'publication_date': '2024-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00074821.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tepmetko:0,TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,,,Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,MET exon 14 skipping,locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC),TEPMETKO (tepotinib),,,,,,,,doc:hc.tepmetko,Document,Regulatory approval,Tepmetko (tepotinib) [product monograph]. HC.,"EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.","EMD Serono, a Division of EMD Inc., Canada",Tepmetko,tepotinib,2021-05-27,2025-06-13,2024-03-04,https://pdf.hres.ca/dpd_pm/00074821.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,415,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 68, 'name': 'MET Exon 14 (Deletion)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],90,,,Drug,Tepotinib,ncit:C88314,C88314,Tepotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2246,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,180,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2247,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,181,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2248,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,182,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2249,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,183,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2250,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,184,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2251,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:1,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,,,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,IDH1 R132,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,190,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2252,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:1,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,,,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,IDH1 R132,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,191,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2253,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:1,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,,,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,IDH1 R132,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,192,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2254,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:1,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,,,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,IDH1 R132,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,193,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2255,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': '2024-07-19', 'access_date': '2025-06-13', 'publication_date': '2024-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00076398.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tibsovo:0,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,,,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,IDH1 R132 mutation,acute myeloid leukemia (AML),"Tibsovo (ivosidenib), azacitidine",,,,,,,,doc:hc.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [product monograph]. HC.,Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.,Servier Canada Inc.,Tibsovo,ivosidenib,2024-07-19,2025-06-13,2024-07-19,https://pdf.hres.ca/dpd_pm/00076398.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,194,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2256,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [product monograph]. HC.', 'citation': 'Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.', 'company': 'Gilead Sciences Canada, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': '2025-05-14', 'access_date': '2025-06-13', 'publication_date': '2025-05-14', 'url': 'https://pdf.hres.ca/dpd_pm/00080546.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.trodelvy:0,"TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",,,"Health Canada approved sacituzumab govitecan for the treatment of adult  patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","HR-positive, HER2-negative,",unresectable locally advanced or metastatic breast cancer,Trodelvy (sacituzumab govitecan),,,,,,,,doc:hc.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [product monograph]. HC.,"Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.","Gilead Sciences Canada, Inc.",Trodelvy,sacituzumab govitecan,2025-05-14,2025-06-13,2025-05-14,https://pdf.hres.ca/dpd_pm/00080546.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,404,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2257,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [product monograph]. HC.', 'citation': 'Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.', 'company': 'Gilead Sciences Canada, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': '2025-05-14', 'access_date': '2025-06-13', 'publication_date': '2025-05-14', 'url': 'https://pdf.hres.ca/dpd_pm/00080546.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.trodelvy:0,"TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",,,"Health Canada approved sacituzumab govitecan for the treatment of adult  patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","HR-positive, HER2-negative,",unresectable locally advanced or metastatic breast cancer,Trodelvy (sacituzumab govitecan),,,,,,,,doc:hc.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [product monograph]. HC.,"Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.","Gilead Sciences Canada, Inc.",Trodelvy,sacituzumab govitecan,2025-05-14,2025-06-13,2025-05-14,https://pdf.hres.ca/dpd_pm/00080546.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,405,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2258,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,53,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2259,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,54,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2260,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,55,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2261,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,56,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2262,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,57,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2263,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,58,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2264,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,59,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2265,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,60,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2266,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,61,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2267,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,62,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2268,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,63,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2269,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,64,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2270,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,65,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2271,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,66,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2272,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,67,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2273,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,68,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2274,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,69,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2275,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,70,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2276,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,71,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2277,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,72,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2278,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [product monograph]. HC.', 'citation': 'AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2024-01-24', 'access_date': '2025-06-13', 'publication_date': '2025-01-03', 'url': 'https://pdf.hres.ca/dpd_pm/00078178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.truqap:0,"TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",,,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",locally advanced or metastatic breast cancer,"Truqap (capivasertib), fulvestrant",,,,,,,,doc:hc.truqap,Document,Regulatory approval,Truqap (capivasertib) [product monograph]. HC.,AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.,AstraZeneca Canada Inc.,Truqap,capivasertib,2024-01-24,2025-06-13,2025-01-03,https://pdf.hres.ca/dpd_pm/00078178.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,718,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 88, 'name': 'PIK3CA amplification', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2279,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tukysa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tukysa (tucatinib) [product monograph]. HC.', 'citation': 'Seagen Inc. Tukysa (tucatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062119.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Tukysa', 'drug_name_generic': 'tucatinib', 'first_published': '2020-06-03', 'access_date': '2025-06-13', 'publication_date': '2021-07-08', 'url': 'https://pdf.hres.ca/dpd_pm/00062119.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98955', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tukysa:0,"TUKYSA (tucatinib) is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.",,,"Health Canada approved tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.",HER2-positive,locally advanced unresectable or metastatic breast cancer,"Tukysa (tucatinib), trastuzumab, capecitabine",,,,,,,,doc:hc.tukysa,Document,Regulatory approval,Tukysa (tucatinib) [product monograph]. HC.,Seagen Inc. Tukysa (tucatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062119.PDF. Revised July 2021. Accessed June 2025.,Seagen Inc.,Tukysa,tucatinib,2020-06-03,2025-06-13,2021-07-08,https://pdf.hres.ca/dpd_pm/00062119.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98955,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,425,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],84,AND,"[{'id': 95, 'conceptType': 'Drug', 'name': 'Tucatinib', 'primaryCoding': {'id': 'ncit:C77896', 'code': 'C77896', 'name': 'Tucatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77896']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2280,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.tykerb', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tykerb (lapatinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Tykerb (lapatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064944.PDF. Revised March 2022. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tykerb', 'drug_name_generic': 'lapatinib', 'first_published': '2009-01-05', 'access_date': '2025-06-13', 'publication_date': '2022-03-02', 'url': 'https://pdf.hres.ca/dpd_pm/00064944.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.tykerb:0,"TYKERB (lapatinib tablets) is indicated for in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.",,,"Health Canada approved lapatinib in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.",HER2 overexpression,metastatic breast cancer,"Tykerb (lapatinib), capecitabine",,,,,,,,doc:hc.tykerb,Document,Regulatory approval,Tykerb (lapatinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Tykerb (lapatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064944.PDF. Revised March 2022. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Tykerb,lapatinib,2009-01-05,2025-06-13,2022-03-02,https://pdf.hres.ca/dpd_pm/00064944.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,195,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],34,AND,"[{'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 96, 'conceptType': 'Drug', 'name': 'Lapatinib', 'primaryCoding': {'id': 'ncit:C26653', 'code': 'C26653', 'name': 'Lapatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2281,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.vectibix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vectibix (panitumumab) [product monograph]. HC.', 'citation': 'Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Vectibix', 'drug_name_generic': 'panitumumab', 'first_published': '2008-04-03', 'access_date': '2025-06-13', 'publication_date': '2021-10-25', 'url': 'https://pdf.hres.ca/dpd_pm/00063326.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79412', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.vectibix:1,"VECTIBIX (panitumumab for injection) is indicated as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",,,"Health Canada approved panitumumab as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.","wild-type KRAS, wild-type NRAS",metastatic colorectal carcinoma (mCRC),Vectibix (panitumumab),,,,,,,,doc:hc.vectibix,Document,Regulatory approval,Vectibix (panitumumab) [product monograph]. HC.,Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.,Amgen Canada Inc.,Vectibix,panitumumab,2008-04-03,2025-06-13,2021-10-25,https://pdf.hres.ca/dpd_pm/00063326.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79412,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,692,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 27, 'name': 'Wild type NRAS', 'genes': [{'id': 33, 'name': 'NRAS', 'primaryCoding': {'id': 'hgnc:7989', 'code': 'HGNC:7989', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002524.5', 'code': 'NM_002524.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000213281', 'code': 'ENSG00000213281', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000213281']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4893', 'code': '4893', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4893']}}], 'extensions': [{'name': 'location', 'value': '1p13.2'}, {'name': 'location_sortable', 'value': '01p13.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],97,,,Drug,Panitumumab,ncit:C1857,C1857,Panitumumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2282,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:0,"VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",,,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","HR-positive, HER2-negative",early breast cancer,"Verzenio (abemaciclib), endocrine therapy",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,0,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2283,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:0,"VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",,,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","HR-positive, HER2-negative",early breast cancer,"Verzenio (abemaciclib), endocrine therapy",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,1,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2284,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:0,"VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",,,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","HR-positive, HER2-negative",early breast cancer,"Verzenio (abemaciclib), endocrine therapy",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,2,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2285,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,792,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2286,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,793,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2287,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,794,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2288,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,12,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2289,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,13,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2290,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': ' Verzenio (abemaciclib) [product monograph]. HC.', 'citation': 'Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Eli Lilly Canada Inc.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': '2019-04-04', 'access_date': '2025-06-13', 'publication_date': '2023-12-01', 'url': 'https://pdf.hres.ca/dpd_pm/00073683.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.verzenio:1,"VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",,,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","HR-positive, HER2-negative",advanced or metastatic breast cancer,"Verzenio (abemaciclib), aromatase inhibitor, fulvestrant",,,,,,,,doc:hc.verzenio,Document,Regulatory approval, Verzenio (abemaciclib) [product monograph]. HC.,Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.,Eli Lilly Canada Inc.,Verzenio,abemaciclib,2019-04-04,2025-06-13,2023-12-01,https://pdf.hres.ca/dpd_pm/00073683.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,14,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2291,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:hc.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [product monograph]. HC.', 'citation': 'Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.', 'company': 'Bayer Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2019-07-04', 'access_date': '2025-06-13', 'publication_date': '2024-09-03', 'url': 'https://pdf.hres.ca/dpd_pm/00076917.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.vitrakvi:0,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,,,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,NTRK gene fusion,solid tumours,Vitrakvi (larotrectinib),,,,,,,,doc:hc.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [product monograph]. HC.,Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.,Bayer Inc.,Vitrakvi,larotrectinib,2019-07-04,2025-06-13,2024-09-03,https://pdf.hres.ca/dpd_pm/00076917.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,199,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 63, 'name': 'v::NTRK1', 'genes': [{'id': 35, 'name': 'NTRK1', 'primaryCoding': {'id': 'hgnc:8031', 'code': 'HGNC:8031', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002529.4', 'code': 'NM_002529.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000198400', 'code': 'ENSG00000198400', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000198400']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4914', 'code': '4914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4914']}}], 'extensions': [{'name': 'location', 'value': '1q23.1'}, {'name': 'location_sortable', 'value': '01q23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2292,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:hc.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [product monograph]. HC.', 'citation': 'Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.', 'company': 'Bayer Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2019-07-04', 'access_date': '2025-06-13', 'publication_date': '2024-09-03', 'url': 'https://pdf.hres.ca/dpd_pm/00076917.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.vitrakvi:0,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,,,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,NTRK gene fusion,solid tumours,Vitrakvi (larotrectinib),,,,,,,,doc:hc.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [product monograph]. HC.,Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.,Bayer Inc.,Vitrakvi,larotrectinib,2019-07-04,2025-06-13,2024-09-03,https://pdf.hres.ca/dpd_pm/00076917.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,200,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 64, 'name': 'v::NTRK2', 'genes': [{'id': 36, 'name': 'NTRK2', 'primaryCoding': {'id': 'hgnc:8032', 'code': 'HGNC:8032', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000148053', 'code': 'ENSG00000148053', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000148053']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4915', 'code': '4915', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4915']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006180.6', 'code': 'NM_006180.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6']}}], 'extensions': [{'name': 'location', 'value': '9q21.33'}, {'name': 'location_sortable', 'value': '09q21.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2293,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:hc.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [product monograph]. HC.', 'citation': 'Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.', 'company': 'Bayer Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2019-07-04', 'access_date': '2025-06-13', 'publication_date': '2024-09-03', 'url': 'https://pdf.hres.ca/dpd_pm/00076917.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.vitrakvi:0,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,,,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,NTRK gene fusion,solid tumours,Vitrakvi (larotrectinib),,,,,,,,doc:hc.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [product monograph]. HC.,Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.,Bayer Inc.,Vitrakvi,larotrectinib,2019-07-04,2025-06-13,2024-09-03,https://pdf.hres.ca/dpd_pm/00076917.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,201,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 65, 'name': 'v::NTRK3', 'genes': [{'id': 37, 'name': 'NTRK3', 'primaryCoding': {'id': 'hgnc:8033', 'code': 'HGNC:8033', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001012338.3', 'code': 'NM_001012338.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140538', 'code': 'ENSG00000140538', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140538']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4916', 'code': '4916', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4916']}}], 'extensions': [{'name': 'location', 'value': '15q25.3'}, {'name': 'location_sortable', 'value': '15q25.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2294,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,479,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2295,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,480,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2296,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,481,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2297,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,482,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2298,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,483,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2299,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,484,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 111, 'name': 'IDH2 p.R172K', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.515G>A'}, {'name': 'protein_change', 'value': 'p.R172K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2300,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,485,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 112, 'name': 'IDH2 p.R172M', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.515G>T'}, {'name': 'protein_change', 'value': 'p.R172M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2301,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,486,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 113, 'name': 'IDH2 p.R172G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.514A>G'}, {'name': 'protein_change', 'value': 'p.R172G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>C'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2302,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,487,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 114, 'name': 'IDH2 p.R172S', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631837}, {'name': 'end_position', 'value': 90631837}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.516G>C'}, {'name': 'protein_change', 'value': 'p.R172S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519736'}, {'name': 'hgvsg', 'value': '15:g.90631837C>G'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2303,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,488,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 115, 'name': 'IDH2 p.R172W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.514A>T'}, {'name': 'protein_change', 'value': 'p.R172W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2304,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,489,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2305,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,490,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2306,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,491,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2307,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,492,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2308,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,493,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2309,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,494,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 111, 'name': 'IDH2 p.R172K', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.515G>A'}, {'name': 'protein_change', 'value': 'p.R172K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2310,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,495,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 112, 'name': 'IDH2 p.R172M', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.515G>T'}, {'name': 'protein_change', 'value': 'p.R172M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2311,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,496,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 113, 'name': 'IDH2 p.R172G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.514A>G'}, {'name': 'protein_change', 'value': 'p.R172G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>C'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2312,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,497,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 114, 'name': 'IDH2 p.R172S', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631837}, {'name': 'end_position', 'value': 90631837}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.516G>C'}, {'name': 'protein_change', 'value': 'p.R172S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519736'}, {'name': 'hgvsg', 'value': '15:g.90631837C>G'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2313,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [product monograph]. HC.', 'citation': 'Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.', 'company': 'Servier Canada Inc.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-27', 'access_date': '2025-06-13', 'publication_date': '2024-08-27', 'url': 'https://pdf.hres.ca/dpd_pm/00076841.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.voranigo:0,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,,,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,IDH1 mutation or IDH2 mutation,Grade 2a astrocytoma or oligodendroglioma,Voranigo (vorasidenib),,,,,,,,doc:hc.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [product monograph]. HC.,Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.,Servier Canada Inc.,Voranigo,vorasidenib,2024-08-27,2025-06-13,2024-08-27,https://pdf.hres.ca/dpd_pm/00076841.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,498,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 115, 'name': 'IDH2 p.R172W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.514A>T'}, {'name': 'protein_change', 'value': 'p.R172W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2314,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.vyloy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vyloy (zolbetuximab) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Vyloy (zolbetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078035.PDF. Published December 2024. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Vyloy', 'drug_name_generic': 'zolbetuximab', 'first_published': '2024-12-13', 'access_date': '2025-06-13', 'publication_date': '2024-12-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078035.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104288', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.vyloy:0,"Vyloy (zolbetuximab for injection), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.",,,"Health Canada approved zolbetuximab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.","HER2-negative, CLDN18.2 >= 75%",locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma,"Vyloy (zolbetuximab), fluoropyrimidine, platinum-containing chemotherapy",,,,,,,,doc:hc.vyloy,Document,Regulatory approval,Vyloy (zolbetuximab) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Vyloy (zolbetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078035.PDF. Published December 2024. Accessed June 2025.","Astellas Pharma Canada, Inc.",Vyloy,zolbetuximab,2024-12-13,2025-06-13,2024-12-13,https://pdf.hres.ca/dpd_pm/00078035.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104288,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,514,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 103, 'name': 'CLDN18.2 >= 75%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CLDN18.2'}, {'name': 'unit', 'value': 'Percentage of tumor cells'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.75'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],97,AND,"[{'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 111, 'conceptType': 'Drug', 'name': 'Zolbetuximab', 'primaryCoding': {'id': 'ncit:C85475', 'code': 'C85475', 'name': 'Zolbetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C85475']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CLDN18.2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2315,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': '2012-04-25', 'access_date': '2025-06-13', 'publication_date': '2023-04-17', 'url': 'https://pdf.hres.ca/dpd_pm/00070448.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xalkori:0,XALKORI (crizotinib) is indicated for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,,,Health Canada approved crizotinib for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,ALK-positive,locally advanced or metastatic non-small cell lung cancer (NSCLC),XALKORI (crizotinib),,,,,,,,doc:hc.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [product monograph]. HC.,Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.,Pfizer Canada ULC,Xalkori,crizotinib,2012-04-25,2025-06-13,2023-04-17,https://pdf.hres.ca/dpd_pm/00070448.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,84,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2316,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [product monograph]. HC.', 'citation': 'Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': '2012-04-25', 'access_date': '2025-06-13', 'publication_date': '2023-04-17', 'url': 'https://pdf.hres.ca/dpd_pm/00070448.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xalkori:1,XALKORI (crizotinib) is indicated for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,,,Health Canada approved crizotinib for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,ROS1-positive,locally advanced or metastatic non-small cell lung cancer (NSCLC),XALKORI (crizotinib),,,,,,,,doc:hc.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [product monograph]. HC.,Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.,Pfizer Canada ULC,Xalkori,crizotinib,2012-04-25,2025-06-13,2023-04-17,https://pdf.hres.ca/dpd_pm/00070448.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,85,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2317,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,709,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 66, 'name': 'FLT3-ITD', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'requires_oncogenic', 'value': True}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2318,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,710,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 85, 'name': 'FLT3 p.D835Y', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2503G>T'}, {'name': 'protein_change', 'value': 'p.D835Y'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2319,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,152,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 116, 'name': 'FLT3 p.D835A', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2504A>C'}, {'name': 'protein_change', 'value': 'p.D835A'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>G'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2320,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,153,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 117, 'name': 'FLT3 p.D835E', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592640}, {'name': 'end_position', 'value': 28592640}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2505T>G'}, {'name': 'protein_change', 'value': 'p.D835E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913487'}, {'name': 'hgvsg', 'value': '13:g.28592640A>C'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2321,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,154,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 118, 'name': 'FLT3 p.D835H', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2503G>C'}, {'name': 'protein_change', 'value': 'p.D835H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>G'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2322,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,155,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 119, 'name': 'FLT3 p.D835N', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2503G>A'}, {'name': 'protein_change', 'value': 'p.D835N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>T'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2323,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,156,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 120, 'name': 'FLT3 p.D835S', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'TC'}, {'name': 'alternate_allele', 'value': 'CT'}, {'name': 'cdna_change', 'value': 'c.2503_2504delinsAG'}, {'name': 'protein_change', 'value': 'p.D835S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'ENST00000241453.7:c.2503_2504delinsAG'}, {'name': 'hgvsg', 'value': '13:g.28592641_28592642delinsCT'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2324,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [product monograph]. HC.', 'citation': 'Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Astellas Pharma Canada, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': '2019-12-23', 'access_date': '2025-06-13', 'publication_date': '2022-01-04', 'url': 'https://pdf.hres.ca/dpd_pm/00064190.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.xospata:0,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,,,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,FLT3 mutation,relapsed or refactory acute myeloid leukemia (AML),Xospata (gilteritinib),,,,,,,,doc:hc.xospata,Document,Regulatory approval,Xospata (gilteritinib) [product monograph]. HC.,"Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.","Astellas Pharma Canada, Inc.",Xospata,gilteritinib,2019-12-23,2025-06-13,2022-01-04,https://pdf.hres.ca/dpd_pm/00064190.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,157,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 121, 'name': 'FLT3 p.D835V', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2504A>T'}, {'name': 'protein_change', 'value': 'p.D835V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>A'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2325,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2012-02-01', 'access_date': '2025-06-13', 'publication_date': '2023-12-07', 'url': 'https://pdf.hres.ca/dpd_pm/00074279.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.yervoy:0,"YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",,,"Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",PD-L1  1% with no EGFR or ALK genomic tumour aberrations,metastatic non-small cell lung cancer (NSCLC),"Yervoy (ipilimumab), nivolumab",,,,,,,,doc:hc.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.,Bristol-Myers Squibb Canada,Yervoy,ipilimumab,2012-02-01,2025-06-13,2023-12-07,https://pdf.hres.ca/dpd_pm/00074279.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,171,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2326,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2012-02-01', 'access_date': '2025-06-13', 'publication_date': '2023-12-07', 'url': 'https://pdf.hres.ca/dpd_pm/00074279.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.yervoy:1,"YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",,,"Health Canada approved ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",no EGFR or ALK genomic tumour aberrations,metastatic non-small cell lung cancer (NSCLC),"Yervoy (ipilimumab), nivolumab, 2 cycles of platinum-doublet chemotherapy",,,,,,,,doc:hc.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.,Bristol-Myers Squibb Canada,Yervoy,ipilimumab,2012-02-01,2025-06-13,2023-12-07,https://pdf.hres.ca/dpd_pm/00074279.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,173,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],31,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2327,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [product monograph]. HC.', 'citation': 'Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2012-02-01', 'access_date': '2025-06-13', 'publication_date': '2023-12-07', 'url': 'https://pdf.hres.ca/dpd_pm/00074279.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525', 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.yervoy:3,"YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",,,"Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",PD-L1  1%,unresectable or metastatic esophageal squamous cell carcinoma (ESCC),"Yervoy (ipilimumab), nivolumab",,,,,,,,doc:hc.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [product monograph]. HC.,Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.,Bristol-Myers Squibb Canada,Yervoy,ipilimumab,2012-02-01,2025-06-13,2023-12-07,https://pdf.hres.ca/dpd_pm/00074279.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,642,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",82,Disease,Esophageal Squamous Cell Carcinoma,oncotree:ESCC,ESCC,Esophageal Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,hc
2328,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.zelboraf', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zelboraf (vemurafenib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Zelboraf', 'drug_name_generic': 'vemurafenib', 'first_published': None, 'access_date': '2025-06-13', 'publication_date': '2019-12-10', 'url': 'https://pdf.hres.ca/dpd_pm/00054278.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.zelboraf:0,ZELBORAF (vemurafenib) is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,,,Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,BRAF V600,unresectable or metastatic melanoma,Zelboraf (vemurafenib),,,,,,,,doc:hc.zelboraf,Document,Regulatory approval,Zelboraf (vemurafenib) [product monograph]. HC.,Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.,Hoffmann-La Roche Limited,Zelboraf,vemurafenib,,2025-06-13,2019-12-10,https://pdf.hres.ca/dpd_pm/00054278.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,426,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],22,,,Drug,Vemurafenib,ncit:C64768,C64768,Vemurafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2329,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.zelboraf', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zelboraf (vemurafenib) [product monograph]. HC.', 'citation': 'Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Zelboraf', 'drug_name_generic': 'vemurafenib', 'first_published': None, 'access_date': '2025-06-13', 'publication_date': '2019-12-10', 'url': 'https://pdf.hres.ca/dpd_pm/00054278.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.zelboraf:0,ZELBORAF (vemurafenib) is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,,,Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,BRAF V600,unresectable or metastatic melanoma,Zelboraf (vemurafenib),,,,,,,,doc:hc.zelboraf,Document,Regulatory approval,Zelboraf (vemurafenib) [product monograph]. HC.,Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.,Hoffmann-La Roche Limited,Zelboraf,vemurafenib,,2025-06-13,2019-12-10,https://pdf.hres.ca/dpd_pm/00054278.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,711,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],22,,,Drug,Vemurafenib,ncit:C64768,C64768,Vemurafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2330,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.zykadia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zykadia (ceritinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Zykadia', 'drug_name_generic': 'ceritinib', 'first_published': '2015-03-27', 'access_date': '2025-06-13', 'publication_date': '2022-02-25', 'url': 'https://pdf.hres.ca/dpd_pm/00064867.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.zykadia:0,ZYKADIA (ceritinib) as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,,,Health Canada approved ceritinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,ALK-positive,metastaic non-small cell lung cancer (NSCLC),Zykadia (ceritinib),,,,,,,,doc:hc.zykadia,Document,Regulatory approval,Zykadia (ceritinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Zykadia,ceritinib,2015-03-27,2025-06-13,2022-02-25,https://pdf.hres.ca/dpd_pm/00064867.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,77,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],106,,,Drug,Ceritinib,ncit:C115112,C115112,Ceritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115112'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
2331,Statement,,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:hc.zykadia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zykadia (ceritinib) [product monograph]. HC.', 'citation': 'Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Zykadia', 'drug_name_generic': 'ceritinib', 'first_published': '2015-03-27', 'access_date': '2025-06-13', 'publication_date': '2022-02-25', 'url': 'https://pdf.hres.ca/dpd_pm/00064867.PDF', 'url_drug': None, 'application_number': None, 'organization': {'id': 'hc', 'name': 'Health Canada', 'description': 'Regulatory agency that approves drugs for sale and use in Canada.', 'url': 'https://health-products.canada.ca/dpd-bdpp/', 'last_updated': '2025-06-11'}}]",supports,ind:hc.zykadia:1,ZYKADIA (ceritinib) as monotherapy is indicated for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.,,,Health Canada approved ceritinib for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.,ALK-positive,locally advanced or metastatic NSCLC,Zykadia (ceritinib),,,,,,,,doc:hc.zykadia,Document,Regulatory approval,Zykadia (ceritinib) [product monograph]. HC.,Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.,Novartis Pharmaceuticals Canada Inc.,Zykadia,ceritinib,2015-03-27,2025-06-13,2022-02-25,https://pdf.hres.ca/dpd_pm/00064867.PDF,,,hc,Health Canada,Regulatory agency that approves drugs for sale and use in Canada.,https://health-products.canada.ca/dpd-bdpp/,2025-06-11,77,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],106,,,Drug,Ceritinib,ncit:C115112,C115112,Ceritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115112'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",hc
